

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Topoisomerases and cancer chemotherapy: recent... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1704/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1704" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Topoisomerases and cancer chemotherapy: recent advances and unanswered questions" />
    
            <meta name="og:title" content="F1000Research Article: Topoisomerases and cancer chemotherapy: recent advances and unanswered questions.">
            <meta name="og:description" content="Read the latest article version by Mary-Ann Bjornsti, Scott H. Kaufmann, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="22188">
            <meta name="article-id" content="20201">
            <meta name="dc.title" content="Topoisomerases and cancer chemotherapy: recent advances and unanswered questions">
            <meta name="dc.description" content="DNA topoisomerases are enzymes that catalyze changes in the torsional and flexural strain of DNA molecules. Earlier studies implicated these enzymes in a variety of processes in both prokaryotes and eukaryotes, including DNA replication, transcription, recombination, and chromosome segregation. Studies performed over the past 3 years have provided new insight into the roles of various topoisomerases in maintaining eukaryotic chromosome structure and facilitating the decatenation of daughter chromosomes at cell division. In addition, recent studies have demonstrated that the incorporation of ribonucleotides into DNA results in trapping of topoisomerase I (TOP1)&ndash;DNA covalent complexes during aborted ribonucleotide removal. Importantly, such trapped TOP1&ndash;DNA covalent complexes, formed either during ribonucleotide removal or as a consequence of drug action, activate several repair processes, including processes involving the recently described nuclear proteases SPARTAN and GCNA-1. A variety of new TOP1 inhibitors and formulations, including antibody&ndash;drug conjugates and PEGylated complexes, exert their anticancer effects by also trapping these TOP1&ndash;DNA covalent complexes. Here we review recent developments and identify further questions raised by these new findings.">
            <meta name="dc.subject" content="DNA supercoiling, DNA-protein crosslink, DNA-activated protease, topoisomerase poison, chromatin organization ">
            <meta name="dc.creator" content="Bjornsti, Mary-Ann">
            <meta name="dc.creator" content="Kaufmann, Scott H.">
            <meta name="dc.date" content="2019/09/30">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.20201.1">
            <meta name="dc.source" content="F1000Research 2019 8:1704">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="DNA supercoiling">
            <meta name="prism.keyword" content="DNA-protein crosslink">
            <meta name="prism.keyword" content="DNA-activated protease">
            <meta name="prism.keyword" content="topoisomerase poison">
            <meta name="prism.keyword" content="chromatin organization ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/09/30">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1704">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.20201.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1704">
            <meta name="citation_title" content="Topoisomerases and cancer chemotherapy: recent advances and unanswered questions">
            <meta name="citation_abstract" content="DNA topoisomerases are enzymes that catalyze changes in the torsional and flexural strain of DNA molecules. Earlier studies implicated these enzymes in a variety of processes in both prokaryotes and eukaryotes, including DNA replication, transcription, recombination, and chromosome segregation. Studies performed over the past 3 years have provided new insight into the roles of various topoisomerases in maintaining eukaryotic chromosome structure and facilitating the decatenation of daughter chromosomes at cell division. In addition, recent studies have demonstrated that the incorporation of ribonucleotides into DNA results in trapping of topoisomerase I (TOP1)&ndash;DNA covalent complexes during aborted ribonucleotide removal. Importantly, such trapped TOP1&ndash;DNA covalent complexes, formed either during ribonucleotide removal or as a consequence of drug action, activate several repair processes, including processes involving the recently described nuclear proteases SPARTAN and GCNA-1. A variety of new TOP1 inhibitors and formulations, including antibody&ndash;drug conjugates and PEGylated complexes, exert their anticancer effects by also trapping these TOP1&ndash;DNA covalent complexes. Here we review recent developments and identify further questions raised by these new findings.">
            <meta name="citation_description" content="DNA topoisomerases are enzymes that catalyze changes in the torsional and flexural strain of DNA molecules. Earlier studies implicated these enzymes in a variety of processes in both prokaryotes and eukaryotes, including DNA replication, transcription, recombination, and chromosome segregation. Studies performed over the past 3 years have provided new insight into the roles of various topoisomerases in maintaining eukaryotic chromosome structure and facilitating the decatenation of daughter chromosomes at cell division. In addition, recent studies have demonstrated that the incorporation of ribonucleotides into DNA results in trapping of topoisomerase I (TOP1)&ndash;DNA covalent complexes during aborted ribonucleotide removal. Importantly, such trapped TOP1&ndash;DNA covalent complexes, formed either during ribonucleotide removal or as a consequence of drug action, activate several repair processes, including processes involving the recently described nuclear proteases SPARTAN and GCNA-1. A variety of new TOP1 inhibitors and formulations, including antibody&ndash;drug conjugates and PEGylated complexes, exert their anticancer effects by also trapping these TOP1&ndash;DNA covalent complexes. Here we review recent developments and identify further questions raised by these new findings.">
            <meta name="citation_keywords" content="DNA supercoiling, DNA-protein crosslink, DNA-activated protease, topoisomerase poison, chromatin organization ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Mary-Ann Bjornsti">
            <meta name="citation_author_institution" content="Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, 35294-0019, USA">
            <meta name="citation_author" content="Scott H. Kaufmann">
            <meta name="citation_author_institution" content="Departments of Oncology and Molecular Pharmacolgy &amp; Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA">
            <meta name="citation_publication_date" content="2019/09/30">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1704">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.20201.1">
            <meta name="citation_firstpage" content="1704">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1704/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1704.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=22188 /> <input type=hidden id=articleId name=articleId value=20201 /> <input type=hidden id=xmlUrl value="/articles/8-1704/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1704-v1.xml"> <input type=hidden id=article_uuid value=46ee00b9-d4d9-47b2-9593-4f35a3e39253 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Topoisomerases and cancer chemotherapy: recent advances and unanswered questions"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.20201.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.20201.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1704"
  },
  "headline": "Topoisomerases and cancer chemotherapy: recent advances and unanswered questions",
  "datePublished": "2019-09-30T11:43:42",
  "dateModified": "2019-09-30T11:43:42",
  "author": [
    {
      "@type": "Person",
      "name": "Mary-Ann Bjornsti"
    },    {
      "@type": "Person",
      "name": "Scott H. Kaufmann"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "DNA topoisomerases are enzymes that catalyze changes in the torsional and flexural strain of DNA molecules. Earlier studies implicated these enzymes in a variety of processes in both prokaryotes and eukaryotes, including DNA replication, transcription, recombination, and chromosome segregation. Studies performed over the past 3 years have provided new insight into the roles of various topoisomerases in maintaining eukaryotic chromosome structure and facilitating the decatenation of daughter chromosomes at cell division. In addition, recent studies have demonstrated that the incorporation of ribonucleotides into DNA results in trapping of topoisomerase I (TOP1)&ndash;DNA covalent complexes during aborted ribonucleotide removal. Importantly, such trapped TOP1&ndash;DNA covalent complexes, formed either during ribonucleotide removal or as a consequence of drug action, activate several repair processes, including processes involving the recently described nuclear proteases SPARTAN and GCNA-1. A variety of new TOP1 inhibitors and formulations, including antibody&ndash;drug conjugates and PEGylated complexes, exert their anticancer effects by also trapping these TOP1&ndash;DNA covalent complexes. Here we review recent developments and identify further questions raised by these new findings."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1704",
            "name": "Topoisomerases and cancer chemotherapy: recent advances and unanswered..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Topoisomerases and cancer chemotherapy: recent advances and unanswered... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=22188 data-id=20201 data-downloads="" data-views="" data-scholar="10.12688/f1000research.20201.1" data-recommended="" data-doi="10.12688/f1000research.20201.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1704/v1/pdf?article_uuid=46ee00b9-d4d9-47b2-9593-4f35a3e39253" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-20201-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-20201-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-20201-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Bjornsti MA and Kaufmann SH. Topoisomerases and cancer chemotherapy: recent advances and unanswered questions [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1704 (<a class=new-orange href="https://doi.org/10.12688/f1000research.20201.1" target=_blank>https://doi.org/10.12688/f1000research.20201.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-20201-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=20201 id=track-article-signin-20201 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/20201?target=/articles/8-1704">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=22188 /> <input name=articleId type=hidden value=20201 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Topoisomerases and cancer chemotherapy: recent advances and unanswered questions</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:bjornsti@uab.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Mary-Ann Bjornsti</span></a><a href="https://orcid.org/0000-0002-6983-6282" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6983-6282</div><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:Kaufmann.Scott@Mayo.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Scott H. Kaufmann</span></a><a href="https://orcid.org/0000-0002-4900-7145" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4900-7145</div><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:bjornsti@uab.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Mary-Ann Bjornsti</span></a><a href="http://orcid.org/0000-0002-6983-6282" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6983-6282</div><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:Kaufmann.Scott@Mayo.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Scott H. Kaufmann</span></a><a href="http://orcid.org/0000-0002-4900-7145" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4900-7145</div><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 30 Sep 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.20201.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, 35294-0019, USA<br/> <sup>2</sup> Departments of Oncology and Molecular Pharmacolgy &amp; Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA<br/> <p> <div class=margin-bottom> Mary-Ann Bjornsti <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Validation, Writing  Review & Editing </div> <div class=margin-bottom> Scott H. Kaufmann <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Validation, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=57286-54096></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=57284-54094></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=57283-54093></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> DNA topoisomerases are enzymes that catalyze changes in the torsional and flexural strain of DNA molecules. Earlier studies implicated these enzymes in a variety of processes in both prokaryotes and eukaryotes, including DNA replication, transcription, recombination, and chromosome segregation. Studies performed over the past 3 years have provided new insight into the roles of various topoisomerases in maintaining eukaryotic chromosome structure and facilitating the decatenation of daughter chromosomes at cell division. In addition, recent studies have demonstrated that the incorporation of ribonucleotides into DNA results in trapping of topoisomerase I (TOP1)DNA covalent complexes during aborted ribonucleotide removal. Importantly, such trapped TOP1DNA covalent complexes, formed either during ribonucleotide removal or as a consequence of drug action, activate several repair processes, including processes involving the recently described nuclear proteases SPARTAN and GCNA-1. A variety of new TOP1 inhibitors and formulations, including antibodydrug conjugates and PEGylated complexes, exert their anticancer effects by also trapping these TOP1DNA covalent complexes. Here we review recent developments and identify further questions raised by these new findings. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> DNA supercoiling, DNA-protein crosslink, DNA-activated protease, topoisomerase poison, chromatin organization </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Mary-Ann Bjornsti (<a href="mailto:bjornsti@uab.edu">bjornsti@uab.edu</a>) <br> Scott H. Kaufmann (<a href="mailto:Kaufmann.Scott@Mayo.edu">Kaufmann.Scott@Mayo.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Mary-Ann Bjornsti, Scott H. Kaufmann </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Dr. Kaufmann indicates that he is the named co-inventor on a patent held by Mayo Clinic regarding the use of antibodies to TOPccs as theranostic reagents. Dr Bjornsti declared that she has no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> Supported in part by National Institutes of Health (NIH) grants P30 CA013148-45 (M-AB), P50 CA136393 (SHK) and R01 CA190423 (SHK). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2019 Bjornsti MA and Kaufmann SH. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Bjornsti MA and Kaufmann SH. Topoisomerases and cancer chemotherapy: recent advances and unanswered questions [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1704 (<a href="https://doi.org/10.12688/f1000research.20201.1" target=_blank>https://doi.org/10.12688/f1000research.20201.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 30 Sep 2019, <b>8</b>(F1000 Faculty Rev):1704 (<a href="https://doi.org/10.12688/f1000research.20201.1" target=_blank>https://doi.org/10.12688/f1000research.20201.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 30 Sep 2019, <b>8</b>(F1000 Faculty Rev):1704 (<a href="https://doi.org/10.12688/f1000research.20201.1" target=_blank>https://doi.org/10.12688/f1000research.20201.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d14871e151>Introduction</h2><p class="" id=d14871e154>The helical structure of duplex DNA provides a physical basis for the faithful duplication and deciphering of genetic information while also ensuring DNA strand integrity. The intertwining of the two complementary polynucleotide strands is stabilized by hydrogen bonding and stacking interactions between the hydrophobic bases. Yet these features also impose topological constraints during processes involving DNA<sup><a href="#ref-1">1</a><a href="#ref-4">4</a></sup>. For example, during DNA replication, each strand serves as a template for polymerization of a complementary strand. However, the progressive unwinding of antiparallel DNA strands may cause overwinding (positive supercoiling) ahead of the replication fork and intertwining of daughter DNA molecules (precatenanes) behind the fork. Similar topological considerations apply to transcription, which induces local unwinding (negative supercoiling) of the DNA helix behind the advancing RNA polymerase complex and positive supercoiling ahead of it.</p><p class="" id=d14871e164>The ability of cells to resolve local domains of DNA supercoiling and separate multiply intertwined DNA molecules is critical for gene expression, recombination, DNA replication, and chromosome segregation, yet it must be achieved while still maintaining chromosomal integrity. Solutions to these problems involve a family of enzymes called DNA topoisomerases, which catalyze changes in the linkage of DNA strands (or helices) by nicking one or both strands of the DNA duplex and, at the same time, becoming covalently linked to one end of the cleaved DNA through a phosphotyrosyl bond. After another DNA strand (or duplex) is passed through the protein-linked break(s) to produce a change in DNA topology, the original phosphodiester bond is religated to restore integrity of the DNA backbone.</p><p class="" id=d14871e167>As detailed in <a href="#T1">Table 1</a>, topoisomerases perform critical functions in all kingdoms of life and can be divided into five subfamilies (type IA, IB, IC, IIA, and IIB) based on the number of DNA strands cleaved (one or two, for type I or II, respectively), the nature of the covalent phosphotyrosyl intermediate formed (5 or 3 linkage), and other aspects of enzyme structure and catalysis (see <a href="#f1">Figure 1</a>). Nevertheless, these enzymes all share a common mechanism of transient breakage and rejoining of DNA strand(s).</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. DNA topoisomerases.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d14871e187 class=n-a></a><thead><a name=d14871e189 class=n-a></a><tr><a name=d14871e191 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e193 class=n-a></a>Subfamily<a href="#TFN1">*</a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e198 class=n-a></a>Mechanism</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e201 class=n-a></a>Activity<sup><a href="#TFN2">#</a></sup></th><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e207 class=n-a></a>Representative<br class=br>enzymes</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e212 class=n-a></a>Structure</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e216 class=n-a></a>Organism</th></tr></thead><tbody><a name=d14871e221 class=n-a></a><tr><a name=d14871e223 class=n-a></a><td align=left colspan=1 rowspan=6 valign=top><a name=d14871e225 class=n-a></a>Type IA (5) </td><td align=left colspan=1 rowspan=6 valign=top><a name=d14871e228 class=n-a></a>Enzyme-bridged<br class=br>single DNA<br class=br>strand passage </td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e235 class=n-a></a>Relaxation of () DNA </td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e238 class=n-a></a>Bacterial DNA<br class=br>topoisomerase I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e243 class=n-a></a>Monomer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e247 class=n-a></a><i>Escherichia coli</i></td></tr><tr><a name=d14871e252 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e254 class=n-a></a>Decatenation<sup><a href="#ref-14">14</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e260 class=n-a></a>Bacterial DNA<br class=br>topoisomerase III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e265 class=n-a></a>Monomer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e268 class=n-a></a><i>E. coli</i></td></tr><tr><a name=d14871e273 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e275 class=n-a></a>Introduce (+)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e278 class=n-a></a>Archaeal reverse gyrase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e281 class=n-a></a>Monomer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e284 class=n-a></a><i>Archaeoglobus fulgidus</i></td></tr><tr><a name=d14871e289 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d14871e291 class=n-a></a>Decatenation, resolve<br class=br>recombination<br class=br>intermediates with<br class=br>helicase<sup><a href="#ref-15">15</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e303 class=n-a></a>Eukaryal DNA<br class=br>topoisomerase III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e308 class=n-a></a>Monomer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e311 class=n-a></a><i>Saccharomyces</i><br class=br><i>cerevisiae</i></td></tr><tr><a name=d14871e319 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e321 class=n-a></a>Eukaryal DNA<br class=br>topoisomerase III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e326 class=n-a></a>Monomer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e329 class=n-a></a><i>Homo sapiens</i></td></tr><tr><a name=d14871e335 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e337 class=n-a></a>Regulates transcription</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e340 class=n-a></a>Eukaryal DNA<br class=br>topoisomerase III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e345 class=n-a></a>Monomer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e348 class=n-a></a><i>H. sapiens</i></td></tr><tr><a name=d14871e353 class=n-a></a><td align=left colspan=1 rowspan=4 valign=top><a name=d14871e355 class=n-a></a>Type IB (3)</td><td align=left colspan=1 rowspan=4 valign=top><a name=d14871e358 class=n-a></a>Enzyme-linked<br class=br>DNA strand<br class=br>rotation</td><td align=left colspan=1 rowspan=4 valign=top><a name=d14871e365 class=n-a></a>Relaxation of (+) and ()<br class=br>DNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e370 class=n-a></a>Poxvirus DNA<br class=br>topoisomerase I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e375 class=n-a></a>Monomer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e379 class=n-a></a>Vaccinia virus</td></tr><tr><a name=d14871e383 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e385 class=n-a></a>Trypanosome DNA<br class=br>topoisomerase I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e390 class=n-a></a>Heterodimer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e393 class=n-a></a><i>Leishmania donovani</i></td></tr><tr><a name=d14871e398 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e400 class=n-a></a>Eukaryal DNA<br class=br>topoisomerase I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e405 class=n-a></a>Monomer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e408 class=n-a></a><i>H. sapiens/S. cerevisiae</i></td></tr><tr><a name=d14871e413 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e415 class=n-a></a>Mitochondrial DNA<br class=br>topoisomerase I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e420 class=n-a></a>Monomer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e423 class=n-a></a><i>H. sapiens</i></td></tr><tr><a name=d14871e428 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e430 class=n-a></a>Type IC (3)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e433 class=n-a></a>Enzyme-linked<br class=br>DNA strand<br class=br>rotation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e440 class=n-a></a>Relaxation of (+) and ()<br class=br>DNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e445 class=n-a></a>Archaeal DNA<br class=br>topoisomerase V</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e450 class=n-a></a>Monomer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e454 class=n-a></a><i>Methanopyrus kandleri</i></td></tr><tr><a name=d14871e460 class=n-a></a><td align=left colspan=1 rowspan=5 valign=top><a name=d14871e462 class=n-a></a>Type IIA (5)</td><td align=left colspan=1 rowspan=5 valign=top><a name=d14871e465 class=n-a></a>Enzyme-bridged<br class=br>duplex DNA<br class=br>passage</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e472 class=n-a></a>Introduction of () into<br class=br>DNA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e477 class=n-a></a>Bacterial DNA<br class=br>gyrase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e482 class=n-a></a>A<sub>2</sub>B<sub>2</sub> heterotetramer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e492 class=n-a></a> <i>E. coli</i> </td></tr><tr><a name=d14871e499 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e501 class=n-a></a>Relaxation of (+),<br class=br>decatenation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e506 class=n-a></a>Bacterial DNA<br class=br>topoisomerase IV</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e511 class=n-a></a>C<sub>2</sub>D<sub>2</sub> heterotetramer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e520 class=n-a></a><i>E. coli</i></td></tr><tr><a name=d14871e525 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d14871e527 class=n-a></a>Relaxation of (+) and ()<br class=br>DNA/decatenation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e532 class=n-a></a>Eukaryal DNA<br class=br>topoisomerase II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e537 class=n-a></a>Homodimer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e540 class=n-a></a><i>S. cerevisiae</i></td></tr><tr><a name=d14871e545 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e547 class=n-a></a>Eukaryal DNA<br class=br>topoisomerase II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e552 class=n-a></a>Homodimer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e555 class=n-a></a><i>H. sapiens</i></td></tr><tr><a name=d14871e560 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e562 class=n-a></a>Eukaryal DNA<br class=br>topoisomerase II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e567 class=n-a></a>Homodimer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e570 class=n-a></a><i>H. sapiens</i></td></tr><tr><a name=d14871e575 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d14871e577 class=n-a></a>Type IIB (5)</td><td align=left colspan=1 rowspan=3 valign=top><a name=d14871e580 class=n-a></a>Enzyme-bridged<br class=br>duplex DNA<br class=br>passage</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e587 class=n-a></a>Relaxation of (+) and ()</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e590 class=n-a></a>Archaeal DNA<br class=br>topoisomerase VI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e595 class=n-a></a>A<sub>2</sub>B<sub>2</sub> heterotetramer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e605 class=n-a></a><i>Sulfolobus shibatae</i></td></tr><tr><a name=d14871e611 class=n-a></a><td colspan=1 rowspan=1><a name=d14871e613 class=n-a></a>DNA/decatenation </td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e616 class=n-a></a>Plant DNA<br class=br>topoisomerase VI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e621 class=n-a></a>A<sub>2</sub>B<sub>2</sub> heterotetramer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e630 class=n-a></a><i>Arabidopsis thaliana</i></td></tr><tr><a name=d14871e635 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e637 class=n-a></a>Weak relaxation/<br class=br>decatenation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e642 class=n-a></a>Bacterial DNA<br class=br>topoisomerase<br class=br>VIII<sup><a href="#ref-16">16</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e652 class=n-a></a>Homodimer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e655 class=n-a></a><i>Ammonifex degensii</i></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d14871e664 class=n-a></a><p id=TFN1> <b>*</b>Type I and II enzymes transiently cleave one or two strands of duplex DNA, respectively. As a consequence, type I enzymes catalyze changes in linking number (Lk) in steps of one, while type II enzymes alter Lk in steps of two. Type IA and all type II enzymes form topoisomerase cleavage complexes involving phosphotyrosyl linkages with a 5 DNA end, while type IB and IC enzymes form 3 phosphotyrosine bonds.</p><p id=TFN2><sup><b>#</b></sup>() and (+) refer to negatively and positively supercoiled DNA, respectively.</p></div></div></div><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22188/24027b3d-75e1-4aba-8d99-1cc1b5d8993e_figure1.gif"><img alt="24027b3d-75e1-4aba-8d99-1cc1b5d8993e_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22188/24027b3d-75e1-4aba-8d99-1cc1b5d8993e_figure1.gif"></a><div class=caption><h3>Figure 1. Topoisomerase mechanisms.</h3><p id=d14871e691>In the topoisomerase I cleavage complex (TOP1cc) (top), the 3 DNA end is covalently linked to the active site tyrosine (Y). Changes in the linkage of DNA strands occur through a mechanism of strand rotation, where the untethered 5 DNA end of the cleaved strand swivels about the noncleaved DNA strand. TOP2 (middle) and TOP3 (bottom) both involve mechanisms of DNA strand transfer. In the case of TOP2cc, the G segment of duplex DNA is cleaved by the two active sites of the homodimer, following capture of the T segment by the closure of the N-terminal ATPase domains. The T segment DNA is then successively passed through the double-strand break in the G segment and out through the bottom dimer interface. For type IA enzymes, depicted for TOP3cc, a single strand of negatively supercoiled DNA is cleaved to form a 5 phosphotyrosyl bond, while the 3OH end is held by the enzyme. A conformational change in the protein then allows the intact complementary strand to be passed through the protein-linked break, followed by religation of the cleaved DNA.</p></div></div><p class="" id=d14871e698>Topoisomerase-linked DNA breaks (topoisomerase-cleavage complexes or TOPccs) are integral to topoisomerase-mediated changes in DNA topology but also pose potential threats to genome integrity. For example, trapping of a TOPcc in advance of the replication machinery or during chromosome segregation, where interwound (or catenated) DNA helices are unlinked by topoisomerases, can have dire effects on genome stability and cell viability. Indeed, topoisomerases are the cellular targets of a wide spectrum of antimicrobial and anticancer agents, which either act to stabilize TOPccs (termed poisons) or otherwise inhibit enzyme catalysis to induce DNA damage<sup><a href="#ref-5">5</a><a href="#ref-8">8</a></sup>. This difference between poisons and inhibitors is illustrated in <a href="#f2">Figure 2</a>. In eukaryotes, topoisomerase poisons include camptothecins (topotecan and SN-38, the active metabolite of the drug irinotecan), which stabilize TOP1ccs, and doxorubicin or etoposide, which stabilize TOP2ccs. In addition to these drugs, DNA modifications themselves, such as lesions induced by oxidative damage or ribonucleotides mistakenly incorporated into DNA, may also stabilize TOPccs. Although topoisomerases provide critical solutions to the topological problems imposed by the helical structure of duplex DNA, the hallmark of these activitiesthe formation of a covalent enzymeDNA intermediateconstitutes an inherent threat to genome integrity.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22188/24027b3d-75e1-4aba-8d99-1cc1b5d8993e_figure2.gif"><img alt="24027b3d-75e1-4aba-8d99-1cc1b5d8993e_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22188/24027b3d-75e1-4aba-8d99-1cc1b5d8993e_figure2.gif"></a><div class=caption><h3>Figure 2. Distinct actions of topoisomerase poisons and inhibitors.</h3><p id=d14871e721>(<b>A</b>) As diagrammed for TOP1, a canonical inhibitor would prevent enzyme-mediated cleavage of a single strand of duplex DNA, while a poison (such as camptothecin) acts to stabilize the topoisomerase I cleavage complex (TOP1cc) reaction intermediate, thereby converting a normal enzyme into a source of DNA damage. The same principles apply to TOP2, although, in these instances, the dimeric enzymes produce two enzyme-linked DNA breaks staggered by 4 bp. (<b>B</b>) Based on these distinct modes of action, increased topoisomerase levels in an isogenic cell line would induce opposing effects on drug sensitivity: resistance to an inhibitor versus increased sensitivity to a poison. Shown in this diagram are the dose response curves for killing that result from an increase in topoisomerase levels relative to cells that yield the black curve.</p></div></div><p class="" id=d14871e734>In this review, we focus on recent advances in our understanding of topoisomerase function in eukaryotic cells, the therapeutic targeting of topoisomerases in cancer, and the repair pathways that resolve the resulting drug-induced lesions. While highlighting these advances, we also identify unanswered questions that these new findings raise.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d14871e740>Roles of topoisomerases in nuclear organization and genomic stability</h2><p class="" id=d14871e743>The distinct biological functions of individual topoisomerases and the physiological consequences of altering their activity have been extensively studied (for reviews, see <a href="#ref-1">1</a><a href="#ref-4">4</a>,<a href="#ref-9">9</a>). Nevertheless, the technical challenges of assessing local changes in DNA topology in live cells leave perplexing questions regarding topoisomerase function in maintaining chromosome architecture and genome stability. In this section, we summarize recent studies that highlight surprising aspects of eukaryal topoisomerase function.</p><div class=section><a name=d14871e755 class=n-a></a><h3 class=section-title>Type IB topoisomerases: maintenance of nuclear and mitochondrial genome stability</h3><p class="" id=d14871e760>In eukaryotes, nuclear TOP1 catalyzes the relaxation of local domains of positive and negative supercoils during DNA replication, recombination, transcription, and possibly chromosome condensation<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a>,<a href="#ref-10">10</a></sup>. Stabilization of TOP1ccs by camptothecins during replication is an effective strategy for treating solid tumors and hematologic malignances, as discussed below. During transcription, the phosphorylated C-terminal domain of the catalytic subunit of RNA polymerase II binds and activates TOP1, effectively tethering TOP1 to the transcriptional machinery<sup><a href="#ref-11">11</a>,<a href="#ref-12">12</a></sup>. TOP1 then relaxes positive supercoils, which are generated ahead of the transcription complex and could otherwise impede its progress, as well as negative supercoils behind the transcription complex.</p><p class="" id=d14871e780>In the absence of TOP1, local accumulation of negative supercoils facilitates the formation of R-loops, stable hybrid RNADNA duplexes of the nascent RNA transcripts and template strands. R-loops also allow the formation of secondary structures, such as G-quadraplexes and hairpins, in the single-stranded non-template strand. RNase H1 and H2 can degrade RNA in these RNADNA heteroduplexes. While genome-wide R-loop mapping indicates context-dependent gains and losses in R-loops when TOP1 is depleted<sup><a href="#ref-13">13</a></sup>, it is the increased levels of R-loops and G-quadraplexes that are associated with dysregulation of transcription and replication as well as genome instability.</p><p class="" id=d14871e787>The misincorporation of ribonucleotides into DNA, at rates approaching 10<sup>6</sup> ribonucleotides per genome per replication cycle<sup><a href="#ref-17">17</a></sup>, can also lead to replication stress, single- and double-strand breaks, and small deletions<sup><a href="#ref-18">18</a><a href="#ref-20">20</a></sup>. Ordinarily these ribonucleotides are removed by the concerted action of RNAse H2, DNA polymerase , FLAP endonuclease, and DNA ligase 1<sup><a href="#ref-17">17</a></sup>. However, if ribonucleotides are not removed, TOP1 cleavage of the strand immediately 3 to the ribonucleotide results in the nucleophilic attack of the 2OH of the ribonucleotide on the TOP1cc to generate a 2,3 cyclic phosphate at the 3 DNA end and release of TOP1. A second, upstream TOP1 cleavage event can then liberate a short oligo with the modified 3 end, trapping the TOP1cc across a gap. If DNA strand realignments juxtapose the free 5OH from the first cleavage and the TOP1cc, enzyme-mediated ligation can produce short deletions. In highly transcribed genes, this TOP1-mediated mutagenesis can be exacerbated by the tethering of TOP1 to RNA polII<sup><a href="#ref-21">21</a></sup>.</p><p class="" id=d14871e812>A recent genome-wide CRISPR screen showed that interruption of genes encoding the three subunits of RNase H2 enhances human cell line sensitivity to the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib<sup><a href="#ref-22">22</a></sup>. Further studies attribute this olaparib hypersensitivity to increased ribonucleotide-dependent stabilization of TOP1ccs, which can serve as PARP1 substrates. These observations provide a compelling rationale for inhibiting PARP in order to trigger TOP1cc-initiated killing in cancers with deleted or mutated <i>RNASEH2B</i>.</p><p class="" id=d14871e823>In vertebrates, a second nuclear-encoded type IB topoisomerase (TOP1MT) selectively localizes to mitochondria and catalyzes the relaxation of circular mitochondrial DNA<sup><a href="#ref-23">23</a></sup>. Despite its similarity to nuclear TOP1, TOP1MT does not contribute to camptothecin-induced toxicity. Instead, TOP1MT physically associates with mitochondrial ribosome subunits to promote mitochondrial translation, which is critical for hepatocellular carcinoma cell growth<sup><a href="#ref-24">24</a></sup>. These findings suggest that inhibition of TOP1MT activity, rather than stabilization of TOP1MTccs, might be an effective strategy for targeting this enzyme to treat some cancers.</p></div><div class=section><a name=d14871e835 class=n-a></a><h3 class=section-title>Evolving understanding of eukaryal topoisomerase III and  (TOP3 and )</h3><p class="" id=d14871e840>Distinct from the swivelase activity ascribed to type IB enzymes, type IA topoisomerases exhibit a mechanism of enzyme-bridged strand passage (<a href="#f1">Figure 1</a>)<sup><a href="#ref-25">25</a></sup>. As with bacterial TOPA, eukaryotic TOP3 enzymes (including yeast TOP3) preferentially relax highly negatively supercoiled DNA and decatenate duplex DNA molecules tethered by single-stranded DNA interlinks or hemicatenanes<sup><a href="#ref-26">26</a></sup>. Differential splicing produces nuclear and mitochondrial isoforms of vertebrate TOP3. Nuclear TOP3 forms a complex with the BLM helicase and RMI1 and RMI2 proteins<sup><a href="#ref-27">27</a></sup> to resolve double Holliday junctions during recombination<sup><a href="#ref-28">28</a></sup>. In contrast, mitochondrial TOP3 decatenates newly replicated mtDNA circles, which are linked by a hemicatenane formed at the origin of replication, to allow segregation of replicated mitochondrial genomes<sup><a href="#ref-29">29</a></sup>. Accordingly, TOP3 dysregulation results in human mitochondrial disease.</p><p class="" id=d14871e867>TOP3, another type IA topoisomerase encoded by the <i>TOP3B</i> gene, binds mRNA and functions during neurodevelopment<sup><a href="#ref-30">30</a></sup>. Recent studies, made possible by the development of circular double-stranded and knotted single-stranded RNA substrates, suggest that TOP3 can catalyze RNA topoisomerization<sup><a href="#ref-31">31</a><a href="#ref-33">33</a></sup>. In multicellular organisms, an association with Tudor domain-containing protein 3 (TDRD3) localizes TOP3 to transcriptionally active chromatin and polyribosomes<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>. Although type IA enzymes with RNA topoisomerase activity have been detected in all domains of life<sup><a href="#ref-34">34</a></sup>, the biological significance of RNA topoisomerization requires further study.</p></div><div class=section><a name=d14871e896 class=n-a></a><h3 class=section-title>Contribution of topoisomerase II to chromosome architecture and genomic stability</h3><p class="" id=d14871e901>In eukaryotes, TOP2 is a homodimeric enzyme that relaxes positively or negatively supercoiled DNA and catenates or decatenates duplex DNA via transient breakage of both DNA strands (<a href="#f1">Figure 1</a>). Yeast encode a single TOP2, while human cells express TOP2 and TOP2 enzymes, encoded by the <i>TOP2A</i> and <i>TOP2B</i> genes, respectively. Although human TOP2 enzymes exhibit structural and mechanistic similarities, TOP2 decatenates sister chromatids during chromosome segregation, whereas TOP2 has been implicated in transcription. Several recent studies further define distinct roles of these enzymes in chromosome dynamics.</p><p class="" id=d14871e913>TOP2 plays a surprising and important role in interphase chromatin organization. High-resolution whole-genome chromatin conformation capture (Hi-C), or <i>in situ</i> Hi-C with DNADNA proximity ligation, allows chromatin fragments in close proximity to be identified. These techniques have determined that chromosomes are organized into topologically associated domains (TADs) of ~200 kb to 1 Mb, typically bound by chromatin enriched in transcriptionally active genes. According to current models, DNA is actively extruded through one or paired cohesin rings to generate TADs until DNA bound by the CCCTC binding factor (CTCF) is encountered<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>. Recent studies suggest that CTCF becomes associated with loop anchors and unidirectionally halts DNA extrusion. TOP2 is then recruited to loop anchors to alleviate the positive supercoils induced by cohesin-derived DNA extrusion. The resulting TOP2-induced breaks are transcription independent but correlate with cohesin<sup><a href="#ref-38">38</a></sup>. At a low frequency, unresolved TOP2ccs at these loop anchors can also lead to DNA breakage and translocations<sup><a href="#ref-39">39</a></sup>. Thus, TOP2 involvement in topological dynamics associated with chromosome organization contributes somewhat unexpectedly to chromosome breakage and rearrangements.</p><p class="" id=d14871e934>During chromosome segregation, intertwined DNA duplexes (catenanes) are resolved or decatenated by TOP2 in yeast and TOP2 in human cells. TOP2 enzymes can also readily catenate DNA duplexes in close proximity. Yet increased positive supercoiling drives decatenation, based in part on an intrinsic enzyme bias towards decatenation. A persistent question, then, has been the source of this positive supercoiling to drive decatenation. In yeast, condensin-mediated positive DNA supercoiling increases as cells enter mitosis<sup><a href="#ref-40">40</a></sup>. In human cells, we now know that this positive supercoiling reflects the action of TOP3, which (as part of the TRR complex with RMI1 and RMI2) associates with the Plk1-interacting checkpoint helicase (PICH) to produce extremely high-density positive supercoils<sup><a href="#ref-41">41</a></sup>. Subsequent relaxation of negative supercoils by TOP3 results in the accumulation of positive supercoils, which drives decatenation by TOP2. These studies provide the first evidence for topoisomerase-induced stable domains of positive supercoils in eukaryotic cells and illustrate how DNA extrusion can be locally harnessed to drive chromosome disjunction.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d14871e949>Recognition and resolution of TOPccs</h2><p class="" id=d14871e952>During their catalytic cycles, all topoisomerases transiently form covalent linkages between active site tyrosines and DNA<sup><a href="#ref-42">42</a><a href="#ref-45">45</a></sup>. While the vast majority of these TOPccs are normally resolved by completion of the catalytic cycle, there is increasing interest in the question of what happens when the TOP1 or TOP2 catalytic cycle is slowed or impaired. These issues are particularly critical in the context of anticancer drugs (<a href="#T2">Table 2</a>) and endogenous DNA lesions (abasic sites, oxidized nucleotides, and alkylated bases), which stabilize or trap TOPccs<sup><a href="#ref-46">46</a><a href="#ref-50">50</a></sup>. Thus, the way in which cells deal with TOPccs has biological and pharmacological implications.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. FDA-approved anticancer drugs that increase TOP1- or TOP2-containing DPCs.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d14871e983 class=n-a></a><thead><a name=d14871e985 class=n-a></a><tr><a name=d14871e987 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e989 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e992 class=n-a></a>Target</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e995 class=n-a></a>Clinical status</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e998 class=n-a></a>Clinical uses</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e1001 class=n-a></a>Refs</th></tr></thead><tbody><a name=d14871e1006 class=n-a></a><tr><a name=d14871e1008 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1010 class=n-a></a>Irinotecan</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1013 class=n-a></a>TOP1</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1016 class=n-a></a>FDA approved</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1019 class=n-a></a>Colorectal, pancreatic, and lung cancers</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1022 class=n-a></a><a href="#ref-61">61</a></td></tr><tr><a name=d14871e1027 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1029 class=n-a></a>Topotecan</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1032 class=n-a></a>TOP1</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1035 class=n-a></a>FDA approved</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1038 class=n-a></a>Ovarian, cervical, and small cell lung cancer</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1041 class=n-a></a><a href="#ref-62">62</a>,<a href="#ref-63">63</a></td></tr><tr><a name=d14871e1049 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1051 class=n-a></a>MM398</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1054 class=n-a></a>TOP1</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1057 class=n-a></a>FDA approved</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1060 class=n-a></a>Pancreatic cancer with 5FU and leucovorin</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1063 class=n-a></a><a href="#ref-64">64</a>,<a href="#ref-65">65</a></td></tr><tr><a name=d14871e1071 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1073 class=n-a></a>Etoposide</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1076 class=n-a></a>TOP2</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1079 class=n-a></a>FDA approved</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1082 class=n-a></a>Acute leukemia, lymphoma, testicular cancer,<br class=br>and lung cancers</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1087 class=n-a></a><a href="#ref-66">66</a><a href="#ref-69">69</a></td></tr><tr><a name=d14871e1095 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1097 class=n-a></a>Doxorubicin</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1100 class=n-a></a>TOP2</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1103 class=n-a></a>FDA approved</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1106 class=n-a></a>Breast and bladder cancers, leukemias,<br class=br>lymphomas, and neuroblastoma</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1111 class=n-a></a><a href="#ref-66">66</a>,<a href="#ref-69">69</a>,<a href="#ref-70">70</a></td></tr><tr><a name=d14871e1123 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1125 class=n-a></a>Daunorubicin,<br class=br>idarubicin</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1130 class=n-a></a>TOP2</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1133 class=n-a></a>FDA approved</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1136 class=n-a></a>Acute leukemia</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1139 class=n-a></a><a href="#ref-66">66</a>,<a href="#ref-69">69</a>,<a href="#ref-70">70</a></td></tr><tr><a name=d14871e1150 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1152 class=n-a></a>Mitoxantrone</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1155 class=n-a></a>TOP2</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1158 class=n-a></a>FDA approved</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1161 class=n-a></a>Acute leukemia</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d14871e1164 class=n-a></a><a href="#ref-66">66</a>,<a href="#ref-69">69</a>,<a href="#ref-71">71</a>,<a href="#ref-72">72</a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=TFN3 class=n-a></a><p id=d14871e1184> 5FU, 5-fluorouracil; DPC, DNAprotein crosslinks; FDA, US Food and Drug Administration; TOP1, topoisomerase I; TOP2, topoisomerase II</p></div></div></div><div class=section><a name=d14871e1190 class=n-a></a><h3 class=section-title>TOP1cc removal: multiple pathways and unanswered questions</h3><p class="" id=d14871e1195>DNAprotein crosslinks (DPCs) include not only TOP1ccs, but also crosslinks induced by aldehyde products of demethylation reactions, cisplatin, UV light or ionizing radiation, and trapping of DNA methyltransferases covalently bound to 5-aza-cytosine (reviewed in <a href="#ref-51">51</a><a href="#ref-53">53</a>). Distinct repair pathways have evolved to resolve these DPCs; however, TOPccs present unique challenges because they also involve protein-linked DNA breaks. Recent studies have provided new insight into the action of tyrosyl-DNA phosphodiesterases 1 and 2 (TDP1 and TDP2, respectively) and DNA-dependent proteases such as SPARTAN (also known as SPRTN) that recognize and reverse persistent TOP1ccs.</p><p class="" id=d14871e1204>Several lines of evidence implicate TDP1 in TOP1cc removal.TDP1 can de-esterify peptidic tyrosine-phosphoesters<sup><a href="#ref-54">54</a>,<a href="#ref-55">55</a></sup>, and TDP1 knockdown results in increased foci containing the TOP1 active site peptide covalently bound to DNA<sup><a href="#ref-56">56</a></sup>. Earlier studies suggested that TPD1 efficiently removes short TOP1 peptides from DNA but is less efficient at removing longer peptides or full-length TOP1<sup><a href="#ref-57">57</a></sup>. However, recent studies of TDP1 mutants suggest that full-length TOP1 can, in fact, be released from chromatin-bound TOP1ccs in yeast and human cells<sup><a href="#ref-58">58</a>,<a href="#ref-59">59</a></sup>.</p><p class="" id=d14871e1229>The observation that TDP1 knockdown or knockout has little impact on yeast or mammalian cell sensitivity to camptothecins<sup><a href="#ref-55">55</a>,<a href="#ref-60">60</a></sup> suggested early on that there must be redundant or overlapping repair pathways. In the absence of TDP1, the 5-tyrosyl phosphodiesterase TDP2<sup><a href="#ref-73">73</a>,<a href="#ref-74">74</a></sup> and a pathway involving the repair proteins XPF and ERCC1<sup><a href="#ref-75">75</a></sup> participate in TOP1cc removal. An additional pathway involves cleavage of the adducted DNA by the nuclease MUS81 followed by polymerization and ligation across the resulting gap<sup><a href="#ref-76">76</a></sup>.</p><p class="" id=d14871e1254>Conditions that promote the use of one pathway over another are still being elucidated. Poly(ADP-ribosyl)ation of TDP1 appears to influence this choice<sup><a href="#ref-75">75</a></sup>. In addition, the deubiquitylase UCHL3 was recently shown to regulate TDP1 proteostasis<sup><a href="#ref-77">77</a></sup>, implicating ubiquitin-dependent regulation of TDP1 in the repair of camptothecin-induced TOP1ccs.</p><p class="" id=d14871e1266>Emerging results also suggest a role for proteases in the removal of TOP1ccs. Although early studies implicated the proteasome in this process<sup><a href="#ref-78">78</a><a href="#ref-81">81</a></sup>, the observation that proteasome-mediated TOP1 degradation occurs only at micromolar camptothecin concentrations and not at more clinically relevant low nanomolar concentrations<sup><a href="#ref-56">56</a></sup> calls this model into question. Instead, the nuclear metalloproteinase SPARTAN, which contains a ubiquitin-binding domain and a single-stranded DNA-binding motif<sup><a href="#ref-82">82</a></sup>, has recently been shown to reverse TOP1ccs trapped by normal DNA metabolism or nanomolar camptothecin concentrations<sup><a href="#ref-56">56</a>,<a href="#ref-82">82</a><a href="#ref-84">84</a></sup>. In <i>Saccharomyces cerevisiae</i>, the SPARTAN homolog Wss1 is critical for survival after camptothecin treatment, and the recombinant protease is able to cleave TOP1ccs<sup><a href="#ref-85">85</a></sup>. Likewise, <i>Sprtn</i> downregulation increases TOP1ccs in murine fibroblasts<sup><a href="#ref-56">56</a></sup> and enhances camptothecin sensitivity <i>in vitro</i><sup><a href="#ref-56">56</a>,<a href="#ref-82">82</a>,<a href="#ref-83">83</a></sup>. Mice bearing a hypomorphic <i>Sprtn</i> allele contain increased hepatocyte TOP1ccs and develop hepatic neoplasms<sup><a href="#ref-56">56</a></sup>, which recapitulates Ruijs-Aalfs syndrome, a disorder characterized by germline <i>SPRTN</i> mutations, genomic instability, and early onset hepatocellular carcinoma<sup><a href="#ref-86">86</a><a href="#ref-88">88</a></sup>. This hepatocyte-specific pathology is, at present, poorly understood. Higher TOP1 protein levels<sup><a href="#ref-56">56</a></sup> might contribute to preferential trapping of TOP1ccs in Spartan-deficient hepatocytes, but the possibility that alternative proteases facilitate the removal of TOP1ccs in other tissues also merits investigation. Additional unresolved issues include i) the coupling between proteases and phosphodiesterases or nucleases and ii) the relative contributions of protease-dependent versus protease-independent pathways in TOP1cc removal.</p></div><div class=section><a name=d14871e1344 class=n-a></a><h3 class=section-title>Recognition of trapped TOP1ccs: a plethora of modifications</h3><p class="" id=d14871e1349>A particularly perplexing question is how do trapped TOP1ccs come to be marked for repair or proteolytic degradation? Post-translational modifications of TOP1 and TOP1ccs by ubiquitin<sup><a href="#ref-78">78</a><a href="#ref-81">81</a></sup>, ubiquitin-like modifiers<sup><a href="#ref-89">89</a>,<a href="#ref-90">90</a></sup>, and phosphorylation<sup><a href="#ref-91">91</a><a href="#ref-93">93</a></sup> have been reported, but the physiological relevance of these modifications to TOP1cc resolution is complicated by the use of high camptothecin concentrations.</p><p class="" id=d14871e1373>In this context, studies implicating the small ubiquitin-like modifier (SUMO) in TOP1 action might be pertinent. TOP1 is modified by SUMOylation in CPT-treated yeast and mammalian cells<sup><a href="#ref-89">89</a>,<a href="#ref-90">90</a>,<a href="#ref-94">94</a></sup>. In addition, downregulation or mutation of the sole SUMO E2 ligase Ubc9 is associated with TOP1cc stabilization and enhanced camptothecin toxicity<sup><a href="#ref-89">89</a>,<a href="#ref-90">90</a>,<a href="#ref-95">95</a>,<a href="#ref-96">96</a></sup>. However, recent studies ascribe these effects to a change in Ubc9 substrate specificity<sup><a href="#ref-97">97</a></sup>, consistent with more global changes in SUMOylation of other proteins involved in the DNA damage response and not a direct effect on TOP1.</p><p class="" id=d14871e1403>It is also worth noting that TOP1cc degradation by Wss1 (yeast SPARTAN) occurs in a SUMO-dependent fashion<sup><a href="#ref-98">98</a></sup>, while SPARTAN preferentially binds ubiquitin through a UBZ domain, and its activity is regulated by deubiquitinylation<sup><a href="#ref-82">82</a>,<a href="#ref-99">99</a></sup>. These differences in the SUMO- versus ubiquitin-mediated regulation of Wss1 and SPARTAN, and the inability of SPARTAN to complement <i>wss1</i> yeast cells, led Mailand and colleagues to examine SUMO-dependent responses to various DPCs<sup><a href="#ref-100">100</a></sup>. Their studies implicate SprT metalloproteases of the ACRC/GCNA-1 family in SUMO-dependent resolution of DPCs. While it remains to be determined if GCNA-1 family proteases impact sensitivity to drug-stabilized TOP1ccs, these observations support the notion that other, as-yet-uncharacterized metalloproteases may regulate cellular responses to topoisomerase-mediated DNA damage via distinct ubiquitin-like protein modifications. The potential therapeutic implications of these recently recognized repair pathways remain to be more fully investigated.</p></div><div class=section><a name=d14871e1426 class=n-a></a><h3 class=section-title>Extending the paradigm to TOP2cc</h3><p class="" id=d14871e1431>The machinery responsible for removing trapped TOP2ccs is even less clearly defined. Proteasomal degradation of TOP2 after teniposide treatment has been reported<sup><a href="#ref-101">101</a></sup>, contributing to a model in which collisions between advancing transcription complexes and TOP2ccs result in irreversibly trapped TOP2DNA complexes, which are marked by ubiquitylation and degraded by the proteasome.</p><p class="" id=d14871e1438>More recent studies have identified several alternatives to this model. First, SPARTAN knockdown results in slightly increased levels of TOP2ccs and etoposide sensitivity<sup><a href="#ref-83">83</a></sup>, suggesting SPARTAN might degrade TOP2 before removal of the active site peptide from DNA. Contrary to this model, however, increased TOP2ccs were not observed in MEFs conditionally deleted for <i>Spartan</i>, and MEFs harboring a hypomorphic <i>Spartan</i> allele were not hypersensitive to etoposide<sup><a href="#ref-56">56</a></sup>. Thus, the role of SPARTAN and other nuclear metalloproteinases in the removal of trapped TOP2cc requires further clarification.</p><p class="" id=d14871e1455>Trapped TOP2ccs may also be removed without TOP2 proteolysis. The MRE11 nuclease has been implicated in the removal of TOP2 from DPCs<sup><a href="#ref-102">102</a>,<a href="#ref-103">103</a></sup>. Moreover, TDP1<sup><a href="#ref-104">104</a>,<a href="#ref-105">105</a></sup> and TDP2<sup><a href="#ref-73">73</a>,<a href="#ref-106">106</a></sup> have both been reported to release the TOP2 active site peptide when it is linked to 5OH of the DNA backbone. In particular, TDP2 can reverse covalent binding of TOP2 or TOP2 to a suicide DNA substrate, and this activity increases up to 1000-fold in the presence of the SUMO E3 ligase ZNF451 owing to increased binding of TDP2 to SUMOylated TOP2<sup><a href="#ref-107">107</a></sup>.</p><p class="" id=d14871e1483>Two recent studies further suggest that coordination of SUMO- and Ub-dependent TOP2 modifications may be critical for genomic stability. In etoposide-treated fission yeast, the DNA translocase Rrp2 binds to SUMOylated TOP2ccs and prevents recruitment of the SUMO-dependent E3 ubiquitin ligase STUbL, thereby preventing STUbL-mediated TOP2 ubiquitinylation and degradation<sup><a href="#ref-108">108</a></sup>. Instead, Rrp2 facilitates the eviction of intact TOP2 from the DNA and concomitant DNA resealing, thereby increasing genomic stability and etoposide resistance. In other studies, the Smurf2 E3 ubiquitin ligase was shown to switch the pattern of TOP2 modification from K48 polyubiquitylation that promotes proteasomal degradation to monoubiquitylation, which leads to increased TOP2 protein levels, suppression of anaphase bridge formation, and etoposide resistance<sup><a href="#ref-109">109</a></sup>.</p><p class="" id=d14871e1495>In summary, although multiple pathways have been implicated in the reversal of trapped TOP2ccs, other studies suggest that protecting TOP2ccs from proteolytic degradation is also critical for maintaining genome stability. Further studies are required to assess whether distinct pathways are called into play in response to different levels of DNA damage, as appears to be the case with TOP1, or whether current inconsistencies reflect differential expression of pathway components in different cell types.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d14871e1502>Translating biological knowledge into improved therapy</h2><p class="" id=d14871e1505>The TOP1- and TOP2-targeted drugs in <a href="#T2">Table 2</a> all have activity in the clinical setting, albeit with narrow therapeutic windows. Accordingly, recent efforts to develop topoisomerase poisons<sup><a href="#ref-66">66</a></sup> into more effective antineoplastic agents have tried to address a series of issues.</p><div class=section><a name=d14871e1515 class=n-a></a><h3 class=section-title>Can the delivery and efficacy of topoisomerase poisons be improved?</h3><p class="" id=d14871e1520>Consistent with observations that TOP1 and TOP2 poisons are preferentially toxic during S phase, classic studies demonstrated that the administration of irinotecan on a five-times-daily schedule for 2 weeks is more active against human cancer xenografts than less-protracted schedules<sup><a href="#ref-110">110</a></sup>. Etoposide administered every other day for three doses is likewise more effective against L1210 murine leukemia than a higher dose administered once. In the clinical setting, these observations have been translated into protracted schedules of both irinotecan<sup><a href="#ref-111">111</a></sup> and etoposide<sup><a href="#ref-112">112</a></sup>. Because these prolonged schedules can be inconvenient and toxic<sup><a href="#ref-111">111</a></sup>, there has been an ongoing search for alternatives, including new topoisomerase poisons, drug formulations that extend the half-life of TOPccs, and strategies to increase tumor-selective drug delivery (<a href="#T3">Table 3</a>)<sup><a href="#ref-113">113</a></sup>.</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Emerging inhibitors of mammalian TOP1 or TOP2<sup><a href="#TFN4">a</a></sup>.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d14871e1562 class=n-a></a><tbody><a name=d14871e1564 class=n-a></a><tr><a name=d14871e1566 class=n-a></a><td align=left colspan=1 rowspan=5 valign=top><a name=d14871e1568 class=n-a></a><b>New TOP1 inhibitors</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1572 class=n-a></a>Compound</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1575 class=n-a></a>Unique features and references</td></tr><tr><a name=d14871e1579 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1581 class=n-a></a>STA-8666</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1584 class=n-a></a>1. Covalent fusion of STA-8663 (HSP90 inhibitor) and SN-38 through a cleavable<br class=br>chemical linker<br class=br>2. Prolonged tumor exposure relative to irinotecan <i>in vivo</i><br class=br>3. Very active against small cell lung cancer and sarcoma xenografts<sup><a href="#ref-127">127</a>,<a href="#ref-128">128</a></sup></td></tr><tr><a name=d14871e1602 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1604 class=n-a></a>Indenoisoquinolines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1607 class=n-a></a>1. Stabilize TOP1DNA covalent complexes but lack the lactone ring of<br class=br>camptothecin and its derivatives<br class=br>2. As a consequence, the TOP1DNA covalent complexes do not peak and then<br class=br>decrease as they do with camptothecins<sup><a href="#ref-115">115</a>,<a href="#ref-129">129</a></sup></td></tr><tr><a name=d14871e1623 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1625 class=n-a></a>7-aza-indenoisoquinolines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1628 class=n-a></a>1. These non-camptothecin agents lack the lactone ring that is part of the<br class=br>camptothecin backbone<sup><a href="#ref-130">130</a></sup></td></tr><tr><a name=d14871e1637 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1639 class=n-a></a>Fluoroindenoisoquinolines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1642 class=n-a></a>1. These indenoisoquinoline derivatives contain fluorine in place of methoxy side<br class=br>chains and are more potent than the parent compounds<sup><a href="#ref-131">131</a>,<a href="#ref-132">132</a></sup></td></tr><tr><a name=d14871e1655 class=n-a></a><td align=left colspan=1 rowspan=8 valign=top><a name=d14871e1657 class=n-a></a><b>Novel formulations of</b><br class=br><b>TOP1 inhibitors</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1664 class=n-a></a><b>Antibodydrug</b><br class=br><b>conjugates</b></td><td align=left colspan=1 rowspan=1><a name=d14871e1671 class=n-a></a></td></tr><tr><a name=d14871e1674 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1676 class=n-a></a>DS-8201a</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1679 class=n-a></a>1. Deruxtecan (CPT derivative) covalently coupled to anti-HER2 antibody through<br class=br>cleavable linkage<br class=br>2. Targets HER2-expressing tumors with activity against low-expressing tumor<br class=br>cells<sup><a href="#ref-123">123</a>,<a href="#ref-124">124</a></sup><br class=br>3. Enhances antitumor immunity in mouse model<sup><a href="#ref-133">133</a></sup><br class=br>4. Evidence of activity in clinical trials in HER2<sup>+</sup> trastuzumab emtansine-resistant<br class=br>breast cancer<sup><a href="#ref-125">125</a></sup> and gastric cancer<sup><a href="#ref-126">126</a></sup></td></tr><tr><a name=d14871e1715 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1717 class=n-a></a>U3-1402</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1720 class=n-a></a>1. Deruxtecan covalently coupled to anti-HER3 antibody through cleavable<br class=br>linkage<br class=br>2. Targets HER3-expressing tumor cells<sup><a href="#ref-134">134</a></sup></td></tr><tr><a name=d14871e1731 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1733 class=n-a></a>Sacituzumab Govitecan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1736 class=n-a></a>1. SN-38 covalently coupled to antibody to human trophoblast cell surface antigen<br class=br>(TROP2), a glycoprotein found on several solid tumors<sup><a href="#ref-135">135</a><a href="#ref-137">137</a></sup><br class=br>2. Objective response rates in phase II clinical trials in triple negative breast<br class=br>cancer (30%)<sup><a href="#ref-138">138</a>,<a href="#ref-139">139</a></sup>, non-small cell lung cancer (19%)<sup><a href="#ref-140">140</a></sup>, and metastatic small<br class=br>cell lung cancer (14%)<sup><a href="#ref-141">141</a></sup><br class=br>3. Synergizes with PARP inhibitors in triple-negative breast cancer independent of<br class=br><i>BRCA1/2</i> mutation status<sup><a href="#ref-142">142</a></sup></td></tr><tr><a name=d14871e1778 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1780 class=n-a></a><b>Novel formulations</b></td><td align=left colspan=1 rowspan=1><a name=d14871e1784 class=n-a></a></td></tr><tr><a name=d14871e1787 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1789 class=n-a></a>Di-SN38-phosphatidylcholine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1792 class=n-a></a>1. Liposomes of two SN-38 molecules covalently bound to phosphatidylcholine<br class=br>2. Extended half-life in mice<sup><a href="#ref-143">143</a></sup></td></tr><tr><a name=d14871e1802 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1804 class=n-a></a>Camptothecin or SN-38<br class=br>in functionalized carbon<br class=br>nanotubes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1811 class=n-a></a>1. Encapsulation in carbon nanotubes bearing carboxylate groups on<br class=br>their surfaces enhances solubility in aqueous solution while maintaining<br class=br>antiproliferative effects <i>in vitro</i><sup><a href="#ref-144">144</a></sup></td></tr><tr><a name=d14871e1824 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1826 class=n-a></a>Camptothecin in -<br class=br>cyclodextrin nanosponges</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1831 class=n-a></a>1. Increased solubility and protection from degradation compared to parent CPT<br class=br>2. Active against prostate cancer and anaplastic thyroid carcinoma <i>in vitro</i><sup><a href="#ref-145">145</a>,<a href="#ref-146">146</a></sup></td></tr><tr><a name=d14871e1845 class=n-a></a><td align=left colspan=1 rowspan=6 valign=top><a name=d14871e1847 class=n-a></a><b>Novel TOP2 inhibitors</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1851 class=n-a></a><b>Compound</b></td><td align=left colspan=1 rowspan=1><a name=d14871e1855 class=n-a></a></td></tr><tr><a name=d14871e1858 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1860 class=n-a></a>F14512</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1863 class=n-a></a>1. Polyamine-conjugated etoposide derivative<br class=br>2. Depends on TOP2A for killing<br class=br>3. TOP2cc last longer and do not depend on TDP2 for removal<sup><a href="#ref-147">147</a></sup><br class=br>4. Marrow suppression was dose limiting in a phase I study<sup><a href="#ref-148">148</a></sup></td></tr><tr><a name=d14871e1879 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1881 class=n-a></a>Pixantrone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1884 class=n-a></a>1. Selectively targets TOP2A<br class=br>2. Diminished oxidative stress relative to anthracyclines because it binds less Fe(II)<sup><a href="#ref-149">149</a></sup></td></tr><tr><a name=d14871e1893 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1895 class=n-a></a>Vosaroxin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1898 class=n-a></a>1. Anti-cancer quinolone derivative<br class=br>2. DNA intercalator, with a possible role in sequence-specific TOP2 poisoning<sup><a href="#ref-150">150</a>,<a href="#ref-151">151</a></sup></td></tr><tr><a name=d14871e1911 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1913 class=n-a></a><b>Novel formulations</b></td><td align=left colspan=1 rowspan=1><a name=d14871e1917 class=n-a></a></td></tr><tr><a name=d14871e1920 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1922 class=n-a></a>Dimethylepipodophyllotoxin<br class=br>coupled to specific<br class=br>nucleotide sequence</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e1929 class=n-a></a>1. Demonstrate somewhat selective cleavage of complementary sequence,<br class=br>raising possibility of using coupled oligonucleotides to target TOP1 or TOP2<br class=br>poisons to specific sequences<sup><a href="#ref-152">152</a></sup></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d14871e1944 class=n-a></a><p id=TFN4> <sup>a</sup><a target=xrefwindow href="https://clinicaltrials.gov/" id=d14871e1949>https://clinicaltrials.gov</a></p><p id=d14871e1952>TOP1, topoisomerase I; TOP2, topoisomerase II; TOP2cc, topoisomerase II cleavage complex</p></div></div></div><p class="" id=d14871e1958>Among the new classes of TOP1 or TOP2 poisons, TOP1-directed indenoisoquinolines<sup><a href="#ref-114">114</a>,<a href="#ref-115">115</a></sup> are furthest along in development. These agents, which lack a lactone ring and, in contrast to camptothecin derivatives, do not exist in equilibrium between an active agent and inactive derivative<sup><a href="#ref-115">115</a></sup>, exhibit promising activity against canine lymphomas<sup><a href="#ref-116">116</a></sup>. Assessments of their activity in humans are awaited with interest.</p><p class="" id=d14871e1976>An alternative approach involves new formulations that extend tumor exposure. MM398, a nanoliposomal irinotecan formulation<sup><a href="#ref-117">117</a></sup>, gained FDA approval in combination with 5-fluorouracil and leucovorin for gemcitabine-resistant pancreatic cancer<sup><a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup>. In contrast, NKTR-102, a PEGylated irinotecan, exhibited disappointing activity in breast and ovarian cancer<sup><a href="#ref-118">118</a>,<a href="#ref-119">119</a></sup>. Whether the different outcomes for these two sustained-release irinotecan formulations reflect differences in pharmacokinetics, intratumoral accumulation, or simply choice of tumors studied is not clear.</p><p class="" id=d14871e1998>Santi and coworkers developed an ultra-long-acting Prolynx PEG~SN-38 that accumulates in tumors and delivers active SN-38 rather than the prodrug irinotecan<sup><a href="#ref-120">120</a></sup>. Liposomal topotecan formulations are also being developed<sup><a href="#ref-121">121</a></sup>. Whether the promising preclinical activity seen in experimental tumors, which is thought to reflect enhanced permeability and retention of nanoformulations<sup><a href="#ref-122">122</a></sup>, can be translated into increased clinical efficacy remains to be determined.</p><p class="" id=d14871e2013>Antibodydrug conjugates (<a href="#T3">Table 3</a>) also hold the promise of more selectively delivering TOP1 poisons to tumor cells. DS-8201<sup><a href="#ref-123">123</a>,<a href="#ref-124">124</a></sup>, a conjugate of the TOP1 poison deruxtecan with the anti-HER2 antibody trastuzumab, is currently undergoing extensive preclinical and early clinical testing (<a target=xrefwindow href="https://www.clinicaltrials.gov/" id=d14871e2025>www.ClinicalTrials.gov</a>). Promising clinical activity has been observed in trastuzumab-resistant breast and gastric cancers<sup><a href="#ref-125">125</a>,<a href="#ref-126">126</a></sup>. An immunoconjugate of SN-38 and antibody to human trophoblast cell surface antigen 2 (TROP2), a glycoprotein found on several solid tumors<sup><a href="#ref-135">135</a><a href="#ref-137">137</a></sup>, likewise exhibits promising activity in breast<sup><a href="#ref-138">138</a>,<a href="#ref-139">139</a></sup> and lung cancers<sup><a href="#ref-140">140</a>,<a href="#ref-141">141</a></sup> (<a href="#T3">Table 3</a>).</p></div><div class=section><a name=d14871e2062 class=n-a></a><h3 class=section-title>Should topoisomerase poisons and DNA damage response modulators be combined?</h3><p class="" id=d14871e2067>Because TOP1 and TOP2 poisons lead to DNA damage, there has been substantial interest over the past few years in combining these drugs with several different DNA damage response modulators.</p><p class="" id=d14871e2070><b><i>PARP inhibitors.</i></b> PARP inhibitors (PARPis), which inhibit PARP1 as well as other PARP family members<sup><a href="#ref-153">153</a></sup>, are FDA approved for high-grade serous ovarian cancer, germline <i>BRCA1/2</i>-mutated breast cancer, and <i>BRCA1/2</i>-mutated castration-resistant prostate cancer<sup><a href="#ref-154">154</a><a href="#ref-158">158</a></sup>. Additional studies identified a role for PARP1 in stabilizing<sup><a href="#ref-159">159</a><a href="#ref-161">161</a></sup> and restarting<sup><a href="#ref-162">162</a>,<a href="#ref-163">163</a></sup> stalled replication forks, including forks stalled by TOP1ccs. Consistent with these studies, Curtin <i>et al</i>. demonstrated that PARPis increase killing by TOP1 but not TOP2 poisons<sup><a href="#ref-164">164</a></sup>. This TOP1 poison/PARPi synergy likely results from trapping of inhibited PARP<sup><a href="#ref-165">165</a>,<a href="#ref-166">166</a></sup> at sites of TOP1ccs or TOP1cc-induced DNA damage<sup><a href="#ref-167">167</a></sup>, perhaps in concert with diminished recruitment of TDP1 to TOP1ccs<sup><a href="#ref-75">75</a></sup>.</p><p class="" id=d14871e2130>Building on xenograft studies<sup><a href="#ref-168">168</a>,<a href="#ref-169">169</a></sup>, several clinical trials have evaluated TOP1 poison/PARPi combinations (<a href="#T4">Table 4</a>). Most started with myelosuppressive topotecan or irinotecan regimens<sup><a href="#ref-170">170</a></sup>. Because PARPis also suppress bone marrow function<sup><a href="#ref-171">171</a></sup>, it is not surprising that profound myelosuppression occurs with these combinations, limiting drug doses that can be safely administered together (<a href="#T4">Table 4</a>). In contrast, by starting with a less myelosuppressive weekly topotecan regimen<sup><a href="#ref-172">172</a></sup> and only administering PARPi for 72 hours around each topotecan dose to maximize the synergy, Wahner Hendrickson and coworkers were able to escalate topotecan and veliparib to three-quarters of the single-agent MTDs<sup><a href="#ref-173">173</a></sup>. Whether the approach of i) using a less myelosuppressive TOP1-directed regimen and/or ii) giving intermittent PARPi timed to coincide with maximal TOP1cc stabilization will be an effective way forward with TOP1 poison/PARPi combinations remains to be further assessed.</p><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Recently described combinations of TOP1 or TOP2 poisons with other agents.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d14871e2174 class=n-a></a><thead><a name=d14871e2176 class=n-a></a><tr><a name=d14871e2178 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d14871e2180 class=n-a></a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e2182 class=n-a></a>Topoisomerase poison</th><th align=left colspan=1 rowspan=1 valign=top><a name=d14871e2185 class=n-a></a>Other agent(s)</th><th align=left colspan=2 rowspan=1 valign=top><a name=d14871e2188 class=n-a></a>Observations</th><th align=left colspan=1 rowspan=1><a name=d14871e2191 class=n-a></a>Ref</th></tr></thead><tbody><a name=d14871e2196 class=n-a></a><tr><a name=d14871e2198 class=n-a></a><td align=left colspan=1 rowspan=14 valign=top><a name=d14871e2200 class=n-a></a><b>Preclinical</b><br class=br><b>studies</b></td><td align=left colspan=1 rowspan=1><a name=d14871e2207 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2209 class=n-a></a><b>PARP inhibitors</b></td><td align=left colspan=2 rowspan=1><a name=d14871e2213 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d14871e2215 class=n-a></a></td></tr><tr><a name=d14871e2218 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2220 class=n-a></a>Topotecan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2223 class=n-a></a>Veliparib</td><td align=left colspan=2 rowspan=2 valign=top><a name=d14871e2226 class=n-a></a>Synergy observed at concentrations far below those<br class=br>required to inhibit most PARP activity<br class=br>Transfection with catalytically dead PARP1 also<br class=br>sensitizes</td><td align=left colspan=1 rowspan=2 valign=top><a name=d14871e2235 class=n-a></a><a href="#ref-167">167</a></td></tr><tr><a name=d14871e2240 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2242 class=n-a></a>Camptothecin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2245 class=n-a></a>Niraparib</td></tr><tr><a name=d14871e2249 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d14871e2251 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2253 class=n-a></a><b>ATR inhibitor</b></td><td align=left colspan=2 rowspan=1><a name=d14871e2257 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d14871e2259 class=n-a></a></td></tr><tr><a name=d14871e2262 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2264 class=n-a></a>Topotecan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2267 class=n-a></a>Berzosertib</td><td align=left colspan=2 rowspan=1 valign=top><a name=d14871e2270 class=n-a></a>Sensitization to TOP1 inhibitor in multiple ovarian<br class=br>cancer cell lines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2275 class=n-a></a><a href="#ref-182">182</a></td></tr><tr><a name=d14871e2281 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2283 class=n-a></a>Irinotecan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2286 class=n-a></a>Berzosertib</td><td align=left colspan=2 rowspan=1 valign=top><a name=d14871e2289 class=n-a></a>Enhanced antitumor effects in colorectal xenografts</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2292 class=n-a></a><a href="#ref-183">183</a></td></tr><tr><a name=d14871e2297 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d14871e2299 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2301 class=n-a></a><b>CHK1 inhibitors</b></td><td align=left colspan=2 rowspan=1><a name=d14871e2305 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d14871e2307 class=n-a></a></td></tr><tr><a name=d14871e2310 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2312 class=n-a></a>SN-38</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2315 class=n-a></a>MK-8776</td><td align=left colspan=2 rowspan=1 valign=top><a name=d14871e2318 class=n-a></a>Maximum sensitization when CHK1 inhibitor<br class=br>administered 24 hours after TOP1 poison <i>in vitro</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2325 class=n-a></a><a href="#ref-181">181</a></td></tr><tr><a name=d14871e2330 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2332 class=n-a></a>Irinotecan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2335 class=n-a></a>AZD7762</td><td align=left colspan=2 rowspan=1 valign=top><a name=d14871e2338 class=n-a></a>Sensitization observed in triple-negative breast<br class=br>cancer xenografts</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2343 class=n-a></a><a href="#ref-180">180</a></td></tr><tr><a name=d14871e2348 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d14871e2350 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2352 class=n-a></a><b>CDK inhibitors</b></td><td align=left colspan=2 rowspan=1><a name=d14871e2356 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d14871e2358 class=n-a></a></td></tr><tr><a name=d14871e2361 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2363 class=n-a></a>Irinotecan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2366 class=n-a></a>Palbociclib</td><td align=left colspan=2 rowspan=1 valign=top><a name=d14871e2369 class=n-a></a>Sensitization of colon cancer cells <i>in vitro</i> regardless<br class=br>of presence of hypoxia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2377 class=n-a></a><a href="#ref-218">218</a></td></tr><tr><a name=d14871e2383 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d14871e2385 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2387 class=n-a></a><b>Immune checkpoint inhibitor</b></td><td align=left colspan=2 rowspan=1><a name=d14871e2391 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d14871e2393 class=n-a></a></td></tr><tr><a name=d14871e2396 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2398 class=n-a></a>DS-8201a</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2401 class=n-a></a>Anti-PD-L1</td><td align=left colspan=2 rowspan=1 valign=top><a name=d14871e2404 class=n-a></a>DS-8201a enhances dendritic cell function</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2407 class=n-a></a><a href="#ref-133">133</a></td></tr><tr><a name=d14871e2412 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2414 class=n-a></a>Irinotecan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2417 class=n-a></a>Anti-PD-L1</td><td align=left colspan=2 rowspan=1 valign=top><a name=d14871e2420 class=n-a></a>Irinotecan suppresses regulatory T cells and<br class=br>upregulates MHC class I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2425 class=n-a></a><a href="#ref-198">198</a></td></tr><tr><a name=d14871e2430 class=n-a></a><td align=left colspan=1 rowspan=10 valign=top><a name=d14871e2432 class=n-a></a><b>Clinical studies</b></td><td align=left colspan=1 rowspan=1><a name=d14871e2436 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2438 class=n-a></a><b>PARP inhibitors</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2442 class=n-a></a><b>Clinical trial observations</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2446 class=n-a></a><b>Phase</b></td><td align=left colspan=1 rowspan=1><a name=d14871e2451 class=n-a></a></td></tr><tr><a name=d14871e2454 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2456 class=n-a></a>Topotecan<br class=br>five times daily</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2461 class=n-a></a>Veliparib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2464 class=n-a></a>Dose-limiting hematological AEs<br class=br>Five dose de-escalations to find<br class=br>tolerable dose</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2471 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2474 class=n-a></a><a href="#ref-219">219</a></td></tr><tr><a name=d14871e2479 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2481 class=n-a></a>Topotecan<br class=br>three times daily</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2486 class=n-a></a>Olaparib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2489 class=n-a></a>Dose-limiting hematological AEs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2492 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2495 class=n-a></a><a href="#ref-220">220</a></td></tr><tr><a name=d14871e2501 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2503 class=n-a></a>Topotecan<br class=br>weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2508 class=n-a></a>Veliparib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2511 class=n-a></a>Dose-limiting hematological AEs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2514 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2517 class=n-a></a><a href="#ref-173">173</a></td></tr><tr><a name=d14871e2522 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2524 class=n-a></a>Irinotecan, day 1 and day<br class=br>8 every 21 days</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2529 class=n-a></a>Veliparib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2532 class=n-a></a>Dose-limiting GI and hematological<br class=br>AEs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2537 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2540 class=n-a></a><a href="#ref-221">221</a></td></tr><tr><a name=d14871e2545 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2547 class=n-a></a>Irinotecan every 2 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2550 class=n-a></a>Olaparib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2553 class=n-a></a>Dose-limiting GI and hematological AEs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2556 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2559 class=n-a></a><a href="#ref-222">222</a></td></tr><tr><a name=d14871e2564 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d14871e2566 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2568 class=n-a></a><b>CHK1 inhibitor</b></td><td align=left colspan=1 rowspan=1><a name=d14871e2572 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d14871e2574 class=n-a></a></td></tr><tr><a name=d14871e2577 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2579 class=n-a></a>Irinotecan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2582 class=n-a></a>AZD7762</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2585 class=n-a></a>Dose-limiting cardiotoxicity</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2588 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2591 class=n-a></a><a href="#ref-184">184</a></td></tr><tr><a name=d14871e2596 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d14871e2598 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2600 class=n-a></a><b>ATR inhibitor</b></td><td align=left colspan=1 rowspan=1><a name=d14871e2604 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d14871e2606 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d14871e2608 class=n-a></a></td></tr><tr><a name=d14871e2612 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2614 class=n-a></a>Topotecan</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2617 class=n-a></a>Berzosertib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2620 class=n-a></a>Dose-limiting hematological AEs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2623 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d14871e2626 class=n-a></a><a href="#ref-188">188</a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d14871e2635 class=n-a></a><p id=d14871e2637> AEs, adverse effects; GI, gastrointestinal; MHC, major histocompatibility complex; PARP, poly(ADP-ribose) polymerase; TOP1, topoisomerase I; TOP2, topoisomerase II</p></div></div></div><p class="" id=d14871e2644><b><i>Combinations with ATR and CHK1 inhibitors.</i></b> Stalled replication forks activate the replication checkpoint, a biochemical pathway involving the DNA damage-activated kinases ATR and CHK1 that inhibits new origin firing, stabilizes stalled forks, and increases DNA repair<sup><a href="#ref-174">174</a><a href="#ref-176">176</a></sup>. Consistent with a role for this pathway in cellular recovery from TOP1cc-induced damage<sup><a href="#ref-177">177</a>,<a href="#ref-178">178</a></sup>, inhibition of CHK1<sup><a href="#ref-179">179</a><a href="#ref-181">181</a></sup> or ATR<sup><a href="#ref-182">182</a>,<a href="#ref-183">183</a></sup> sensitizes cancer cells to TOP1 poisons <i>in vitro</i> and in xenografts. Earlier development of a CHK1 inhibitor/TOP1 poison combination<sup><a href="#ref-184">184</a></sup> was abandoned because of off-target cardiac toxicities of the CHK1 inhibitor<sup><a href="#ref-185">185</a></sup>. More recent studies have examined ATR inhibitors (e.g. M6620 and AZD6738)<sup><a href="#ref-186">186</a>,<a href="#ref-187">187</a></sup> with TOP1 poisons. Reportedly, an M6620/topotecan combination was well tolerated, except for myelosuppression, and induced partial responses in two out of 21 (9.5%) patients<sup><a href="#ref-188">188</a></sup>. A phase II trial of this combination in small cell lung cancer (ClinicalTrials.gov identifier: NCT02487095) and a phase I trial of an irinotecan/M6620 combination (NCT02595931) are ongoing.</p><p class="" id=d14871e2701><b><i>TOP1 poison/immune checkpoint inhibitor combinations.</i></b> While immune checkpoint blockade is highly active in certain solid tumors<sup><a href="#ref-189">189</a>,<a href="#ref-190">190</a></sup>, many common cancers respond poorly. However, recent studies suggest that DNA damage can stimulate immune responses through multiple mechanisms. First, release of DNA to the cytosol after DNA damage<sup><a href="#ref-191">191</a></sup> activates the stimulator of interferon genes (STING) pathway<sup><a href="#ref-192">192</a>,<a href="#ref-193">193</a></sup>, leading to the production of pro-inflammatory cytokines. Second, DNA damage-induced release of tumor cell microvesicles can increase immune activation<sup><a href="#ref-194">194</a>,<a href="#ref-195">195</a></sup>. Third, DNA damage increases antigen presentation on tumor cell MHC class I molecules, leading to enhanced dendritic cell activation and T cell responses<sup><a href="#ref-196">196</a></sup>. Importantly, these changes have been observed after treatment with TOP1 poisons, potentially contributing to the synergy observed when irinotecan or DS-8201a is combined with anti-PD-1 <i>in vivo</i><sup><a href="#ref-133">133</a>,<a href="#ref-197">197</a>,<a href="#ref-198">198</a></sup>. Clinical trials are also evaluating TOP2 poisons in combination with PD-1 antibodies (<a target=xrefwindow href="https://www.clinicaltrials.gov/" id=d14871e2748>www.ClinicalTrials.gov</a>).</p></div><div class=section><a name=d14871e2753 class=n-a></a><h3 class=section-title>Predicting response to topoisomerase poisons</h3><p class="" id=d14871e2758>Given the toxicities of topoisomerase poisons, the ability to predict responses and avoid treatment of patients unlikely to benefit would represent a major advance. In isogenic yeast<sup><a href="#ref-199">199</a>,<a href="#ref-200">200</a></sup> or mammalian cells<sup><a href="#ref-201">201</a>,<a href="#ref-202">202</a></sup>, elevated TOP1 or TOP2 levels are associated with increased killing by topoisomerase poisons (<a href="#f2">Figure 2</a>). Additional studies indicate that high TOP1 expression correlates with improved colorectal cancer response to irinotecan<sup><a href="#ref-203">203</a><a href="#ref-206">206</a></sup> and <i>TOP2</i> gene amplification is associated with improved breast cancer response to doxorubicin<sup><a href="#ref-207">207</a>,<a href="#ref-208">208</a></sup>. However, expression and response are not so tightly correlated that outcomes of individual patients can be predicted from expression data alone.</p><p class="" id=d14871e2796>The frequent occurrence of transport-mediated resistance raises the possibility that responses might be better predicted by assaying TOPccs after the first dose of therapy. While earlier techniques for measuring TOPccs were labor intensive and nonspecific, a recently described antibody to TOP1ccs<sup><a href="#ref-209">209</a></sup> opens the possibility of specific, quantitative assays to address the relationship between TOP1ccs and response to TOP1 poisons. Unfortunately, similar reagents to assess TOP2ccs are not currently available.</p><p class="" id=d14871e2803>It is possible that factors other than TOPccs will need to be assessed to predict drug responses. Homologous recombination (HR) defects convey heightened sensitivity to TOP1 and TOP2 poisons in yeast<sup><a href="#ref-210">210</a></sup> and mammalian cells<sup><a href="#ref-167">167</a>,<a href="#ref-211">211</a><a href="#ref-213">213</a></sup>. Moreover, <i>BRCA1</i>- or <i>BRCA2</i>-mutant ovarian cancers have a higher response rate to liposomal doxorubicin<sup><a href="#ref-214">214</a>,<a href="#ref-215">215</a></sup>. Likewise, breast cancers deficient in BRCA1 or HR activity respond better to anthracycline-based neoadjuvant therapy<sup><a href="#ref-216">216</a>,<a href="#ref-217">217</a></sup>. In contrast, <i>BRCA1/2</i> mutation status was not correlated with response to the TOP1 poison topotecan administered alone<sup><a href="#ref-214">214</a></sup> or in combination with PARPi<sup><a href="#ref-173">173</a></sup>. Thus, HR status might need to be considered in predictive algorithms, but the impact of HR status might also vary by drug class.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d14871e2856>Challenges for the coming decade</h2><p class="" id=d14871e2859>As indicated above, recent advances bring into focus a number of topics for future investigation. First, the cellular functions of topoisomerases are incompletely understood, in part because DNA topology still cannot be visualized in intact cells. Second, based on provocative examples, cooperation between various topoisomerases and other enzymes requires further study. Third, when TOPccs are trapped, we still have only rudimentary understanding of the processes that reverse these DPCs and limited insight into the factors that dictate choice between overlapping repair pathways. Finally, even though topoisomerase-directed drugs exhibit anti-neoplastic properties, patients would benefit from more efficacious schedules, more selective delivery of active agents to tumor cells, and potentially bioassays that accurately predict responses to topoisomerase-directed therapy.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d14871e2866 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d16277>References</h2><div class="section ref-list"><a name=d14871e2866 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d14871e2873 class=n-a></a>Champoux JJ: DNA topoisomerases: structure, function, and mechanism. <i>Annu Rev Biochem.</i> 2001; <b>70</b>: 369413. <a target=xrefwindow id=d14871e2881 href="http://www.ncbi.nlm.nih.gov/pubmed/11395412">PubMed Abstract </a> | <a target=xrefwindow id=d14871e2884 href="https://doi.org/10.1146/annurev.biochem.70.1.369">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d14871e2893 class=n-a></a>Wang JC: Cellular roles of DNA topoisomerases: a molecular perspective. <i>Nat Rev Mol Cell Biol.</i> 2002; <b>3</b>(6): 43040. <a target=xrefwindow id=d14871e2901 href="http://www.ncbi.nlm.nih.gov/pubmed/12042765">PubMed Abstract </a> | <a target=xrefwindow id=d14871e2904 href="https://doi.org/10.1038/nrm831">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d14871e2913 class=n-a></a>Seol Y, Neuman KC: The Dynamic Interplay Between DNA Topoisomerases and DNA Topology. <i>Biophys Rev.</i> 2016; <b>8</b>(3): 221231. <a target=xrefwindow id=d14871e2921 href="http://www.ncbi.nlm.nih.gov/pubmed/27942270">PubMed Abstract </a> | <a target=xrefwindow id=d14871e2924 href="https://doi.org/10.1007/s12551-016-0206-x">Publisher Full Text </a> | <a target=xrefwindow id=d14871e2927 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5145260">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d14871e2936 class=n-a></a>Pommier Y, Sun Y, Huang SN, <i> et al.</i>: Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. <i>Nat Rev Mol Cell Biol.</i> 2016; <b>17</b>(11): 703721. <a target=xrefwindow id=d14871e2947 href="http://www.ncbi.nlm.nih.gov/pubmed/27649880">PubMed Abstract </a> | <a target=xrefwindow id=d14871e2950 href="https://doi.org/10.1038/nrm.2016.111">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d14871e2959 class=n-a></a>Vos SM, Tretter EM, Schmidt BH, <i> et al.</i>: All tangled up: how cells direct, manage and exploit topoisomerase function. <i>Nat Rev Mol Cell Biol.</i> 2011; <b>12</b>(12): 82741. <a target=xrefwindow id=d14871e2970 href="http://www.ncbi.nlm.nih.gov/pubmed/22108601">PubMed Abstract </a> | <a target=xrefwindow id=d14871e2973 href="https://doi.org/10.1038/nrm3228">Publisher Full Text </a> | <a target=xrefwindow id=d14871e2977 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4351964">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d14871e2987 class=n-a></a>Pommier Y: Drugging topoisomerases: lessons and challenges. <i>ACS Chem Biol.</i> 2013; <b>8</b>(1): 8295. <a target=xrefwindow id=d14871e2995 href="http://www.ncbi.nlm.nih.gov/pubmed/23259582">PubMed Abstract </a> | <a target=xrefwindow id=d14871e2998 href="https://doi.org/10.1021/cb300648v">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3001 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3549721">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d14871e3010 class=n-a></a>Cuya SM, Bjornsti MA, van Waardenburg RCAM: DNA topoisomerase-targeting chemotherapeutics: what's new? <i>Cancer Chemother Pharmacol.</i> 2017; <b>80</b>(1): 114. <a target=xrefwindow id=d14871e3018 href="http://www.ncbi.nlm.nih.gov/pubmed/28528358">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3021 href="https://doi.org/10.1007/s00280-017-3334-5">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736190800"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3030 class=n-a></a>Bax BD, Murshudov G, Maxwell A, <i> et al.</i>: DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion. <i>J Mol Biol.</i> 2019; <b>431</b>(18): 34273449. <a target=xrefwindow id=d14871e3041 href="http://www.ncbi.nlm.nih.gov/pubmed/31301408">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3044 href="https://doi.org/10.1016/j.jmb.2019.07.008">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3048 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6723622">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736190800">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d14871e3062 class=n-a></a>Ashour ME, Atteya R, El-Khamisy SF: Topoisomerase-mediated chromosomal break repair: an emerging player in many games. <i>Nat Rev Cancer.</i> 2015; <b>15</b>(3): 13751. <a target=xrefwindow id=d14871e3070 href="http://www.ncbi.nlm.nih.gov/pubmed/25693836">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3073 href="https://doi.org/10.1038/nrc3892">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727745036"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3082 class=n-a></a>Kim N, Jinks-Robertson S: The Top1 paradox: Friend and foe of the eukaryotic genome. <i>DNA Repair (Amst).</i> 2017; <b>56</b>: 3341. <a target=xrefwindow id=d14871e3090 href="http://www.ncbi.nlm.nih.gov/pubmed/28641942">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3093 href="https://doi.org/10.1016/j.dnarep.2017.06.005">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3096 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5560766">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727745036">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d14871e3110 class=n-a></a>Wu J, Phatnani HP, Hsieh TS, <i> et al.</i>: The phosphoCTD-interacting domain of Topoisomerase I. <i>Biochem Biophys Res Commun.</i> 2010; <b>397</b>(1): 1179. <a target=xrefwindow id=d14871e3121 href="http://www.ncbi.nlm.nih.gov/pubmed/20493173">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3124 href="https://doi.org/10.1016/j.bbrc.2010.05.081">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3128 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2900466">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726273039"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3138 class=n-a></a>Baranello L, Wojtowicz D, Cui K, <i> et al.</i>: RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription. <i>Cell.</i> 2016; <b>165</b>(2): 35771. <a target=xrefwindow id=d14871e3149 href="http://www.ncbi.nlm.nih.gov/pubmed/27058666">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3152 href="https://doi.org/10.1016/j.cell.2016.02.036">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3156 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4826470">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726273039">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733721510"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3170 class=n-a></a>Manzo SG, Hartono SR, Sanz LA, <i> et al.</i>: DNA Topoisomerase I differentially modulates R-loops across the human genome. <i>Genome Biol.</i> 2018; <b>19</b>(1): 100. <a target=xrefwindow id=d14871e3181 href="http://www.ncbi.nlm.nih.gov/pubmed/30060749">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3184 href="https://doi.org/10.1186/s13059-018-1478-1">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3188 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6066927">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733721510">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734825447"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3202 class=n-a></a>Lee CM, Wang G, Pertsinidis A, <i> et al.</i>: Topoisomerase III Acts at the Replication Fork To Remove Precatenanes. <i>J Bacteriol.</i> 2019; <b>201</b>(7): pii: e00563-18. <a target=xrefwindow id=d14871e3213 href="http://www.ncbi.nlm.nih.gov/pubmed/30617245">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3216 href="https://doi.org/10.1128/JB.00563-18">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3220 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6416919">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734825447">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d14871e3234 class=n-a></a>Oakley TJ, Hickson ID: Defending genome integrity during S-phase: putative roles for RecQ helicases and topoisomerase III. <i>DNA Repair (Amst).</i> 2002; <b>1</b>(3): 175207. <a target=xrefwindow id=d14871e3242 href="http://www.ncbi.nlm.nih.gov/pubmed/12509252">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3245 href="https://doi.org/10.1016/S1568-7864(02)00002-2">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718478387"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3254 class=n-a></a>Gadelle D, Krupovic M, Raymann K, <i> et al.</i>: DNA topoisomerase VIII: a novel subfamily of type IIB topoisomerases encoded by free or integrated plasmids in Archaea and Bacteria. <i>Nucleic Acids Res.</i> 2014; <b>42</b>(13): 857891. <a target=xrefwindow id=d14871e3265 href="http://www.ncbi.nlm.nih.gov/pubmed/24990376">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3268 href="https://doi.org/10.1093/nar/gku568">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3272 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4117785">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718478387">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d14871e3286 class=n-a></a>Williams JS, Lujan SA, Kunkel TA: Processing ribonucleotides incorporated during eukaryotic DNA replication. <i>Nat Rev Mol Cell Biol.</i> 2016; <b>17</b>(6): 35063. <a target=xrefwindow id=d14871e3294 href="http://www.ncbi.nlm.nih.gov/pubmed/27093943">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3297 href="https://doi.org/10.1038/nrm.2016.37">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3300 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5445644">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d14871e3310 class=n-a></a>Kim N, Huang SN, Williams JS, <i> et al.</i>: Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. <i>Science.</i> 2011; <b>332</b>(6037): 15614. <a target=xrefwindow id=d14871e3321 href="http://www.ncbi.nlm.nih.gov/pubmed/21700875">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3324 href="https://doi.org/10.1126/science.1205016">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3328 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3380281">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d14871e3337 class=n-a></a>Williams JS, Smith DJ, Marjavaara L, <i> et al.</i>: Topoisomerase 1-mediated removal of ribonucleotides from nascent leading-strand DNA. <i>Mol Cell.</i> 2013; <b>49</b>(5): 10105. <a target=xrefwindow id=d14871e3348 href="http://www.ncbi.nlm.nih.gov/pubmed/23375499">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3351 href="https://doi.org/10.1016/j.molcel.2012.12.021">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3355 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3595360">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d14871e3364 class=n-a></a>Huang SN, Williams JS, Arana ME, <i> et al.</i>: Topoisomerase I-mediated cleavage at unrepaired ribonucleotides generates DNA double-strand breaks. <i>EMBO J.</i> 2017; <b>36</b>(3): 361373. <a target=xrefwindow id=d14871e3375 href="http://www.ncbi.nlm.nih.gov/pubmed/27932446">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3378 href="https://doi.org/10.15252/embj.201592426">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3382 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5286372">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d14871e3391 class=n-a></a>Cho JE, Jinks-Robertson S: Ribonucleotides and Transcription-Associated Mutagenesis in Yeast. <i>J Mol Biol.</i> 2017; <b>429</b>(21): 31563167. <a target=xrefwindow id=d14871e3399 href="http://www.ncbi.nlm.nih.gov/pubmed/27511624">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3402 href="https://doi.org/10.1016/j.jmb.2016.08.005">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3405 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5296399">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733574619"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3414 class=n-a></a>Zimmermann M, Murina O, Reijns MAM, <i> et al.</i>: CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. <i>Nature.</i> 2018; <b>559</b>(7713): 285289. <a target=xrefwindow id=d14871e3425 href="http://www.ncbi.nlm.nih.gov/pubmed/29973717">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3428 href="https://doi.org/10.1038/s41586-018-0291-z">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3432 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6071917">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733574619">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d14871e3446 class=n-a></a>Sobek S, Boege F: DNA topoisomerases in mtDNA maintenance and ageing. <i>Exp Gerontol.</i> 2014; <b>56</b>: 13541. <a target=xrefwindow id=d14871e3454 href="http://www.ncbi.nlm.nih.gov/pubmed/24440386">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3457 href="https://doi.org/10.1016/j.exger.2014.01.009">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734828530"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3467 class=n-a></a>Baechler SA, Factor VM, Dalla Rosa I, <i> et al.</i>: The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis. <i>Nat Commun.</i> 2019; <b>10</b>(1): 83. <a target=xrefwindow id=d14871e3478 href="http://www.ncbi.nlm.nih.gov/pubmed/30622257">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3481 href="https://doi.org/10.1038/s41467-018-07922-3">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3485 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6325124">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734828530">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d14871e3499 class=n-a></a>Baker NM, Rajan R, Mondragn A: Structural studies of type I topoisomerases. <i>Nucleic Acids Res.</i> 2009; <b>37</b>(3): 693701. <a target=xrefwindow id=d14871e3507 href="http://www.ncbi.nlm.nih.gov/pubmed/19106140">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3510 href="https://doi.org/10.1093/nar/gkn1009">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3513 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2647283">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d14871e3522 class=n-a></a>Plank JL, Chu SH, Pohlhaus JR, <i> et al.</i>: <i>Drosophila melanogaster</i> topoisomerase IIIalpha preferentially relaxes a positively or negatively supercoiled bubble substrate and is essential during development. <i>J Biol Chem.</i> 2005; <b>280</b>(5): 356473. <a target=xrefwindow id=d14871e3536 href="http://www.ncbi.nlm.nih.gov/pubmed/15537633">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3540 href="https://doi.org/10.1074/jbc.M411337200">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d14871e3549 class=n-a></a>Bocquet N, Bizard AH, Abdulrahman W, <i> et al.</i>: Structural and mechanistic insight into Holliday-junction dissolution by topoisomerase III and RMI1. <i>Nat Struct Mol Biol.</i> 2014; <b>21</b>(3): 2618. <a target=xrefwindow id=d14871e3560 href="http://www.ncbi.nlm.nih.gov/pubmed/24509834">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3563 href="https://doi.org/10.1038/nsmb.2775">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3567 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4292918">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d14871e3576 class=n-a></a>Bizard AH, Hickson ID: The dissolution of double Holliday junctions. <i>Cold Spring Harb Perspect Biol.</i> 2014; <b>6</b>(7): a016477. <a target=xrefwindow id=d14871e3584 href="http://www.ncbi.nlm.nih.gov/pubmed/24984776">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3587 href="https://doi.org/10.1101/cshperspect.a016477">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3590 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4067992">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732388921"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3599 class=n-a></a>Nicholls TJ, Nadalutti CA, Motori E, <i> et al.</i>: Topoisomerase 3 Is Required for Decatenation and Segregation of Human mtDNA. <i>Mol Cell.</i> 2018; <b>69</b>(1): 923.e6. <a target=xrefwindow id=d14871e3610 href="http://www.ncbi.nlm.nih.gov/pubmed/29290614">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3613 href="https://doi.org/10.1016/j.molcel.2017.11.033">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3617 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5935120">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732388921">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727160484"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3632 class=n-a></a>Ahmad M, Shen W, Li W, <i> et al.</i>: Topoisomerase 3 is the major topoisomerase for mRNAs and linked to neurodevelopment and mental dysfunction. <i>Nucleic Acids Res.</i> 2017; <b>45</b>(5): 27042713. <a target=xrefwindow id=d14871e3643 href="http://www.ncbi.nlm.nih.gov/pubmed/28039324">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3646 href="https://doi.org/10.1093/nar/gkw1293">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3650 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5389537">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727160484">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d14871e3664 class=n-a></a>Wang H, Di Gate RJ, Seeman NC: An RNA topoisomerase. <i>Proc Natl Acad Sci U S A.</i> 1996; <b>93</b>(18): 947782. <a target=xrefwindow id=d14871e3672 href="http://www.ncbi.nlm.nih.gov/pubmed/8790355">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3675 href="https://doi.org/10.1073/pnas.93.18.9477">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3678 href="http://www.ncbi.nlm.nih.gov/pmc/articles/38453">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d14871e3687 class=n-a></a>Xu D, Shen W, Guo R, <i> et al.</i>: Top3 is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation. <i>Nat Neurosci.</i> 2013; <b>16</b>(9): 123847. <a target=xrefwindow id=d14871e3698 href="http://www.ncbi.nlm.nih.gov/pubmed/23912945">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3701 href="https://doi.org/10.1038/nn.3479">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3705 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3853347">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727464444"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3714 class=n-a></a>Liu D, Shao Y, Chen G, <i> et al.</i>: Synthesizing topological structures containing RNA. <i>Nat Commun.</i> 2017; <b>8</b>: 14936. <a target=xrefwindow id=d14871e3725 href="http://www.ncbi.nlm.nih.gov/pubmed/28361879">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3728 href="https://doi.org/10.1038/ncomms14936">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3732 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5381007">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727464444">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d14871e3746 class=n-a></a>Ahmad M, Xue Y, Lee SK, <i> et al.</i>: RNA topoisomerase is prevalent in all domains of life and associates with polyribosomes in animals. <i>Nucleic Acids Res.</i> 2016; <b>44</b>(13): 633549. <a target=xrefwindow id=d14871e3757 href="http://www.ncbi.nlm.nih.gov/pubmed/27257063">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3760 href="https://doi.org/10.1093/nar/gkw508">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3764 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4994864">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d14871e3773 class=n-a></a>Siaw GE, Liu IF, Lin PY, <i> et al.</i>: DNA and RNA topoisomerase activities of Top3 are promoted by mediator protein Tudor domain-containing protein 3. <i>Proc Natl Acad Sci USA.</i> 2016; <b>113</b>(38): E554451. <a target=xrefwindow id=d14871e3784 href="http://www.ncbi.nlm.nih.gov/pubmed/27582462">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3787 href="https://doi.org/10.1073/pnas.1605517113">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3791 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5035855">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d14871e3801 class=n-a></a>Bjrkegren C, Baranello L: DNA Supercoiling, Topoisomerases, and Cohesin: Partners in Regulating Chromatin Architecture? <i>Int J Mol Sci.</i> 2018; <b>19</b>(3): pii: E884. <a target=xrefwindow id=d14871e3809 href="http://www.ncbi.nlm.nih.gov/pubmed/29547555">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3812 href="https://doi.org/10.3390/ijms19030884">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3815 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5877745">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d14871e3824 class=n-a></a>Fowler F, Tyler JK: Anchoring Chromatin Loops to Cancer. <i>Dev Cell.</i> 2017; <b>42</b>(3): 209211. <a target=xrefwindow id=d14871e3832 href="http://www.ncbi.nlm.nih.gov/pubmed/28787588">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3835 href="https://doi.org/10.1016/j.devcel.2017.07.013">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3838 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5859922">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727835478"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3847 class=n-a></a>Canela A, Maman Y, Jung S, <i> et al.</i>: Genome Organization Drives Chromosome Fragility. <i>Cell.</i> 2017; <b>170</b>(3): 507521.e18. <a target=xrefwindow id=d14871e3858 href="http://www.ncbi.nlm.nih.gov/pubmed/28735753">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3861 href="https://doi.org/10.1016/j.cell.2017.06.034">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3865 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6133249">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727835478">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d14871e3879 class=n-a></a>Vian L, Pkowska A, Rao SSP, <i> et al.</i>: The Energetics and Physiological Impact of Cohesin Extrusion. <i>Cell.</i> 2018; <b>173</b>(5): 11651178.e20. <a target=xrefwindow id=d14871e3890 href="http://www.ncbi.nlm.nih.gov/pubmed/29706548">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3893 href="https://doi.org/10.1016/j.cell.2018.03.072">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3897 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6065110">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d14871e3906 class=n-a></a>Sen N, Leonard J, Torres R, <i> et al.</i>: Physical Proximity of Sister Chromatids Promotes Top2-Dependent Intertwining. <i>Mol Cell.</i> 2016; <b>64</b>(1): 134147. <a target=xrefwindow id=d14871e3917 href="http://www.ncbi.nlm.nih.gov/pubmed/27716481">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3920 href="https://doi.org/10.1016/j.molcel.2016.09.007">Publisher Full Text </a> | <a target=xrefwindow id=d14871e3924 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5065527">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735447580"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e3933 class=n-a></a>Bizard AH, Allemand JF, Hassenkam T, <i> et al.</i>: PICH and TOP3A cooperate to induce positive DNA supercoiling. <i>Nat Struct Mol Biol.</i> 2019; <b>26</b>(4): 267274. <a target=xrefwindow id=d14871e3944 href="http://www.ncbi.nlm.nih.gov/pubmed/30936532">PubMed Abstract </a> | <a target=xrefwindow id=d14871e3947 href="https://doi.org/10.1038/s41594-019-0201-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735447580">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d14871e3962 class=n-a></a>Tse YC, Kirkegaard K, Wang JC: Covalent bonds between protein and DNA. Formation of phosphotyrosine linkage between certain DNA topoisomerases and DNA. <i>J Biol Chem.</i> 1980; <b>255</b>(12): 55605. <a target=xrefwindow id=d14871e3970 href="http://www.ncbi.nlm.nih.gov/pubmed/6155377">PubMed Abstract </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d14871e3979 class=n-a></a>Champoux JJ: DNA is linked to the rat liver DNA nicking-closing enzyme by a phosphodiester bond to tyrosine. <i>J Biol Chem.</i> 1981; <b>256</b>(10): 48059. <a target=xrefwindow id=d14871e3987 href="http://www.ncbi.nlm.nih.gov/pubmed/6262303">PubMed Abstract </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d14871e3996 class=n-a></a>Sander M, Hsieh T: Double strand DNA cleavage by type II DNA topoisomerase from <i>Drosophila melanogaster</i>. <i>J Biol Chem.</i> 1983; <b>258</b>(13): 84218. <a target=xrefwindow id=d14871e4007 href="http://www.ncbi.nlm.nih.gov/pubmed/6305984">PubMed Abstract </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d14871e4016 class=n-a></a>Liu LF, Rowe TC, Yang L, <i> et al.</i>: Cleavage of DNA by mammalian DNA topoisomerase II. <i>J Biol Chem.</i> 1983; <b>258</b>(24): 1536570. <a target=xrefwindow id=d14871e4027 href="http://www.ncbi.nlm.nih.gov/pubmed/6317692">PubMed Abstract </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d14871e4036 class=n-a></a>Pourquier P, Ueng LM, Kohlhagen G, <i> et al.</i>: Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. <i>J Biol Chem.</i> 1997; <b>272</b>(12): 77926. <a target=xrefwindow id=d14871e4047 href="http://www.ncbi.nlm.nih.gov/pubmed/9065442">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4050 href="https://doi.org/10.1074/jbc.272.12.7792">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d14871e4059 class=n-a></a>Pourquier P, Bjornsti MA, Pommier Y: Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct 1,N6-ethenoadenine. <i>J Biol Chem.</i> 1998; <b>273</b>(42): 272459. <a target=xrefwindow id=d14871e4067 href="http://www.ncbi.nlm.nih.gov/pubmed/9765247">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4070 href="https://doi.org/10.1074/jbc.273.42.27245">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d14871e4080 class=n-a></a>Pourquier P, Ueng LM, Fertala J, <i> et al.</i>: Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine. <i>J Biol Chem.</i> 1999; <b>274</b>(13): 851623. <a target=xrefwindow id=d14871e4091 href="http://www.ncbi.nlm.nih.gov/pubmed/10085084">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4094 href="https://doi.org/10.1074/jbc.274.13.8516">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d14871e4103 class=n-a></a>Kingma PS, Corbett AH, Burcham PC, <i> et al.</i>: Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II. DNA lesions as endogenous topoisomerase II poisons. <i>J Biol Chem.</i> 1995; <b>270</b>(37): 214414. <a target=xrefwindow id=d14871e4114 href="http://www.ncbi.nlm.nih.gov/pubmed/7665552">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4117 href="https://doi.org/10.1074/jbc.270.37.21441">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d14871e4126 class=n-a></a>Sabourin M, Osheroff N: Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. <i>Nucleic Acids Res.</i> 2000; <b>28</b>(9): 194754. <a target=xrefwindow id=d14871e4134 href="http://www.ncbi.nlm.nih.gov/pubmed/10756196">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4137 href="https://doi.org/10.1093/nar/28.9.1947">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4140 href="http://www.ncbi.nlm.nih.gov/pmc/articles/103304">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d14871e4149 class=n-a></a>Stingele J, Bellelli R, Boulton SJ: Mechanisms of DNA-protein crosslink repair. <i>Nat Rev Mol Cell Biol.</i> 2017; <b>18</b>(9): 563573. <a target=xrefwindow id=d14871e4157 href="http://www.ncbi.nlm.nih.gov/pubmed/28655905">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4160 href="https://doi.org/10.1038/nrm.2017.56">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d14871e4169 class=n-a></a>Vaz B, Popovic M, Ramadan K: DNA-Protein Crosslink Proteolysis Repair. <i>Trends Biochem Sci.</i> 2017; <b>42</b>(6): 483495. <a target=xrefwindow id=d14871e4177 href="http://www.ncbi.nlm.nih.gov/pubmed/28416269">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4180 href="https://doi.org/10.1016/j.tibs.2017.03.005">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d14871e4189 class=n-a></a>Ide H, Nakano T, Salem AMH, <i> et al.</i>: DNA-protein cross-links: Formidable challenges to maintaining genome integrity. <i>DNA Repair (Amst).</i> 2018; <b>71</b>: 190197. <a target=xrefwindow id=d14871e4200 href="http://www.ncbi.nlm.nih.gov/pubmed/30177436">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4203 href="https://doi.org/10.1016/j.dnarep.2018.08.024">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d14871e4213 class=n-a></a>Yang SW, Burgin AB Jr, Huizenga BN, <i> et al.</i>: A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. <i>Proc Natl Acad Sci U S A.</i> 1996; <b>93</b>(21): 115349. <a target=xrefwindow id=d14871e4224 href="http://www.ncbi.nlm.nih.gov/pubmed/8876170">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4227 href="https://doi.org/10.1073/pnas.93.21.11534">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4231 href="http://www.ncbi.nlm.nih.gov/pmc/articles/38092">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d14871e4240 class=n-a></a>Pouliot JJ, Yao KC, Robertson CA, <i> et al.</i>: Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. <i>Science.</i> 1999; <b>286</b>(5439): 5525. <a target=xrefwindow id=d14871e4251 href="http://www.ncbi.nlm.nih.gov/pubmed/10521354">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4254 href="https://doi.org/10.1126/science.286.5439.552">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d14871e4263 class=n-a></a>Maskey RS, Flatten KS, Sieben CJ, <i> et al.</i>: Spartan deficiency causes accumulation of Topoisomerase 1 cleavage complexes and tumorigenesis. <i>Nucleic Acids Res.</i> 2017; <b>45</b>(8): 45644576. <a target=xrefwindow id=d14871e4274 href="http://www.ncbi.nlm.nih.gov/pubmed/28199696">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4277 href="https://doi.org/10.1093/nar/gkx107">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4281 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5416836">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d14871e4290 class=n-a></a>Interthal H, Champoux JJ: Effects of DNA and protein size on substrate cleavage by human tyrosyl-DNA phosphodiesterase 1. <i>Biochem J.</i> 2011; <b>436</b>(3): 55966. <a target=xrefwindow id=d14871e4298 href="http://www.ncbi.nlm.nih.gov/pubmed/21463258">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4301 href="https://doi.org/10.1042/BJ20101841">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4304 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3151729">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d14871e4313 class=n-a></a>Comeaux EQ, Cuya SM, Kojima K, <i> et al.</i>: Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an alternative nucleophile that can catalyze substrate cleavage. <i>J Biol Chem.</i> 2015; <b>290</b>(10): 620314. <a target=xrefwindow id=d14871e4324 href="http://www.ncbi.nlm.nih.gov/pubmed/25609251">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4327 href="https://doi.org/10.1074/jbc.M114.635284">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4331 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4358259">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d14871e4340 class=n-a></a>Cuya SM, Comeaux EQ, Wanzeck K, <i> et al.</i>: Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin. <i>Oncotarget.</i> 2016; <b>7</b>(52): 8666086674. <a target=xrefwindow id=d14871e4351 href="http://www.ncbi.nlm.nih.gov/pubmed/27893431">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4354 href="https://doi.org/10.18632/oncotarget.13528">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4358 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5349943">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d14871e4368 class=n-a></a>Liu C, Pouliot JJ, Nash HA: Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1. <i>Proc Natl Acad Sci U S A.</i> 2002; <b>99</b>(23): 149705. <a target=xrefwindow id=d14871e4376 href="http://www.ncbi.nlm.nih.gov/pubmed/12397185">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4379 href="https://doi.org/10.1073/pnas.182557199">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4382 href="http://www.ncbi.nlm.nih.gov/pmc/articles/137529">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d14871e4391 class=n-a></a>de Man FM, Goey AKL, van Schaik RHN, <i> et al.</i>: Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. <i>Clin Pharmacokinet.</i> 2018; <b>57</b>(10): 12291254. <a target=xrefwindow id=d14871e4402 href="http://www.ncbi.nlm.nih.gov/pubmed/29520731">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4405 href="https://doi.org/10.1007/s40262-018-0644-7">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4409 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6132501">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d14871e4418 class=n-a></a>Sparreboom A, Zamboni WC: Topoisomerase I-Targeting Drugs. In: Chabner BA, Longo DL, editors. <i>Cancer Chemotherapy and Biotherapy</i>. Fourth ed: Lippincott Williams &amp; Wilkins. 2006; 371413.</span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d14871e4430 class=n-a></a>Riemsma R, Simons JP, Bashir Z, <i> et al.</i>: Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer. <i>BMC Cancer.</i> 2010; <b>10</b>: 436. <a target=xrefwindow id=d14871e4441 href="http://www.ncbi.nlm.nih.gov/pubmed/20716361">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4444 href="https://doi.org/10.1186/1471-2407-10-436">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4448 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2931489">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d14871e4457 class=n-a></a>Wang-Gillam A, Li CP, Bodoky G, <i> et al.</i>: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet.</i> 2016; <b>387</b>(10018): 545557. <a target=xrefwindow id=d14871e4468 href="http://www.ncbi.nlm.nih.gov/pubmed/26615328">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4471 href="https://doi.org/10.1016/S0140-6736(15)00986-1">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d14871e4480 class=n-a></a>Chibaudel B, Maindrault-Gbel F, Bachet JB, <i> et al.</i>: PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. <i>Cancer Med.</i> 2016; <b>5</b>(4): 67683. <a target=xrefwindow id=d14871e4491 href="http://www.ncbi.nlm.nih.gov/pubmed/26806397">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4494 href="https://doi.org/10.1002/cam4.635">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4498 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4831286">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d14871e4508 class=n-a></a>Liu LF: DNA topoisomerase poisons as antitumor drugs. <i>Annu Rev Biochem.</i> 1989; <b>58</b>: 35175. <a target=xrefwindow id=d14871e4516 href="http://www.ncbi.nlm.nih.gov/pubmed/2549853">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4519 href="https://doi.org/10.1146/annurev.bi.58.070189.002031">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d14871e4528 class=n-a></a>Ross W, Rowe T, Glisson B, <i> et al.</i>: Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. <i>Cancer Res.</i> 1984; <b>44</b>(12 Pt 1): 585760. <a target=xrefwindow id=d14871e4539 href="http://www.ncbi.nlm.nih.gov/pubmed/6094001">PubMed Abstract </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d14871e4548 class=n-a></a>Minocha A, Long BH: Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26. <i>Biochem Biophys Res Commun.</i> 1984; <b>122</b>(1): 16570. <a target=xrefwindow id=d14871e4556 href="http://www.ncbi.nlm.nih.gov/pubmed/6331440">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4559 href="https://doi.org/10.1016/0006-291x(84)90454-6">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d14871e4568 class=n-a></a>Nitiss JL: Targeting DNA topoisomerase II in cancer chemotherapy. <i>Nat Rev Cancer.</i> 2009; <b>9</b>(5): 33850. <a target=xrefwindow id=d14871e4576 href="http://www.ncbi.nlm.nih.gov/pubmed/19377506">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4579 href="https://doi.org/10.1038/nrc2607">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4582 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2748742">Free Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d14871e4591 class=n-a></a>Tewey KM, Rowe TC, Yang L, <i> et al.</i>: Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. <i>Science.</i> 1984; <b>226</b>(4673): 4668. <a target=xrefwindow id=d14871e4602 href="http://www.ncbi.nlm.nih.gov/pubmed/6093249">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4605 href="https://doi.org/10.1126/science.6093249">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d14871e4614 class=n-a></a>Glisson B, Gupta R, Hodges P, <i> et al.</i>: Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. <i>Cancer Res.</i> 1986; <b>46</b>(4 Pt 2): 193942. <a target=xrefwindow id=d14871e4625 href="http://www.ncbi.nlm.nih.gov/pubmed/3004712">PubMed Abstract </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d14871e4635 class=n-a></a>Crespi MD, Ivanier SE, Genovese J, <i> et al.</i>: Mitoxantrone affects topoisomerase activities in human breast cancer cells. <i>Biochem Biophys Res Commun.</i> 1986; <b>136</b>(2): 5218. <a target=xrefwindow id=d14871e4646 href="http://www.ncbi.nlm.nih.gov/pubmed/3010982">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4649 href="https://doi.org/10.1016/0006-291x(86)90471-7">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1166208"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e4658 class=n-a></a>Cortes Ledesma F, El Khamisy SF, Zuma MC, <i> et al.</i>: A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. <i>Nature.</i> 2009; <b>461</b>(7264): 6748. <a target=xrefwindow id=d14871e4669 href="http://www.ncbi.nlm.nih.gov/pubmed/19794497">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4672 href="https://doi.org/10.1038/nature08444">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1166208">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d14871e4686 class=n-a></a>Zeng Z, Sharma A, Ju L, <i> et al.</i>: TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1. <i>Nucleic Acids Res.</i> 2012; <b>40</b>(17): 837180. <a target=xrefwindow id=d14871e4697 href="http://www.ncbi.nlm.nih.gov/pubmed/22740648">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4700 href="https://doi.org/10.1093/nar/gks622">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4704 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3458563">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d14871e4713 class=n-a></a>Zhang YW, Regairaz M, Seiler JA, <i> et al.</i>: Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. <i>Nucleic Acids Res.</i> 2011; <b>39</b>(9): 360720. <a target=xrefwindow id=d14871e4724 href="http://www.ncbi.nlm.nih.gov/pubmed/21227924">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4727 href="https://doi.org/10.1093/nar/gkq1304">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4731 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3089458">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d14871e4740 class=n-a></a>Regairaz M, Zhang YW, Fu H, <i> et al.</i>: Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. <i>J Cell Biol.</i> 2011; <b>195</b>(5): 73949. <a target=xrefwindow id=d14871e4751 href="http://www.ncbi.nlm.nih.gov/pubmed/22123861">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4754 href="https://doi.org/10.1083/jcb.201104003">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4758 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3257568">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733444793"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e4767 class=n-a></a>Liao C, Beveridge R, Hudson JJR, <i> et al.</i>: UCHL3 Regulates Topoisomerase-Induced Chromosomal Break Repair by Controlling TDP1 Proteostasis. <i>Cell Rep.</i> 2018; <b>23</b>(11): 33523365. <a target=xrefwindow id=d14871e4778 href="http://www.ncbi.nlm.nih.gov/pubmed/29898404">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4781 href="https://doi.org/10.1016/j.celrep.2018.05.033">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4785 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6019701">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733444793">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d14871e4800 class=n-a></a>Desai SD, Liu LF, Vazquez-Abad D, <i> et al.</i>: Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. <i>J Biol Chem.</i> 1997; <b>272</b>(39): 2415964. <a target=xrefwindow id=d14871e4811 href="http://www.ncbi.nlm.nih.gov/pubmed/9305865">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4814 href="https://doi.org/10.1074/jbc.272.39.24159">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d14871e4823 class=n-a></a>Desai SD, Li TK, Rodriguez-Bauman A, <i> et al.</i>: Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. <i>Cancer Res.</i> 2001; <b>61</b>(15): 592632. <a target=xrefwindow id=d14871e4834 href="http://www.ncbi.nlm.nih.gov/pubmed/11479235">PubMed Abstract </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d14871e4843 class=n-a></a>Desai SD, Zhang H, Rodriguez-Bauman A, <i> et al.</i>: Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. <i>Mol Cell Biol.</i> 2003; <b>23</b>(7): 234150. <a target=xrefwindow id=d14871e4854 href="http://www.ncbi.nlm.nih.gov/pubmed/12640119">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4857 href="https://doi.org/10.1128/mcb.23.7.2341-2350.2003">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4861 href="http://www.ncbi.nlm.nih.gov/pmc/articles/150741">Free Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d14871e4870 class=n-a></a>Lin CP, Ban Y, Lyu YL, <i> et al.</i>: A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. <i>J Biol Chem.</i> 2008; <b>283</b>(30): 2107483. <a target=xrefwindow id=d14871e4881 href="http://www.ncbi.nlm.nih.gov/pubmed/18515798">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4884 href="https://doi.org/10.1074/jbc.M803493200">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4888 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2475699">Free Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d14871e4897 class=n-a></a>Stingele J, Bellelli R, Alte F, <i> et al.</i>: Mechanism and Regulation of DNA-Protein Crosslink Repair by the DNA-Dependent Metalloprotease SPRTN. <i>Mol Cell.</i> 2016; <b>64</b>(4): 688703. <a target=xrefwindow id=d14871e4908 href="http://www.ncbi.nlm.nih.gov/pubmed/27871365">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4911 href="https://doi.org/10.1016/j.molcel.2016.09.031">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4915 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5128726">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d14871e4924 class=n-a></a>Vaz B, Popovic M, Newman JA, <i> et al.</i>: Metalloprotease SPRTN/DVC1 Orchestrates Replication-Coupled DNA-Protein Crosslink Repair. <i>Mol Cell.</i> 2016; <b>64</b>(4): 704719. <a target=xrefwindow id=d14871e4935 href="http://www.ncbi.nlm.nih.gov/pubmed/27871366">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4938 href="https://doi.org/10.1016/j.molcel.2016.09.032">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4942 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5128727">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727169744"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e4952 class=n-a></a>Mrocz M, Zsigmond E, Tth R, <i> et al.</i>: DNA-dependent protease activity of human Spartan facilitates replication of DNA-protein crosslink-containing DNA. <i>Nucleic Acids Res.</i> 2017; <b>45</b>(6): 31723188. <a target=xrefwindow id=d14871e4963 href="http://www.ncbi.nlm.nih.gov/pubmed/28053116">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4966 href="https://doi.org/10.1093/nar/gkw1315">Publisher Full Text </a> | <a target=xrefwindow id=d14871e4970 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5389635">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727169744">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718482808"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e4984 class=n-a></a>Stingele J, Schwarz MS, Bloemeke N, <i> et al.</i>: A DNA-dependent protease involved in DNA-protein crosslink repair. <i>Cell.</i> 2014; <b>158</b>(2): 327338. <a target=xrefwindow id=d14871e4995 href="http://www.ncbi.nlm.nih.gov/pubmed/24998930">PubMed Abstract </a> | <a target=xrefwindow id=d14871e4998 href="https://doi.org/10.1016/j.cell.2014.04.053">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718482808">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d14871e5012 class=n-a></a>Ruijs MW, van Andel RN, Oshima J, <i> et al.</i>: Atypical progeroid syndrome: an unknown helicase gene defect? <i>Am J Med Genet A.</i> 2003; <b>116A</b>(3): 2959. <a target=xrefwindow id=d14871e5023 href="http://www.ncbi.nlm.nih.gov/pubmed/12503110">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5026 href="https://doi.org/10.1002/ajmg.a.10730">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d14871e5035 class=n-a></a>Lessel D, Vaz B, Halder S, <i> et al.</i>: Mutations in <i>SPRTN</i> cause early onset hepatocellular carcinoma, genomic instability and progeroid features. <i>Nat Genet.</i> 2014; <b>46</b>(11): 123944. <a target=xrefwindow id=d14871e5049 href="http://www.ncbi.nlm.nih.gov/pubmed/25261934">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5053 href="https://doi.org/10.1038/ng.3103">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5056 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4343211">Free Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d14871e5065 class=n-a></a>Maskey RS, Kim MS, Baker DJ, <i> et al.</i>: Spartan deficiency causes genomic instability and progeroid phenotypes. <i>Nat Commun.</i> 2014; <b>5</b>: 5744. <a target=xrefwindow id=d14871e5076 href="http://www.ncbi.nlm.nih.gov/pubmed/25501849">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5079 href="https://doi.org/10.1038/ncomms6744">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5083 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4269170">Free Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d14871e5092 class=n-a></a>Mao Y, Sun M, Desai SD, <i> et al.</i>: SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage. <i>Proc Natl Acad Sci U S A.</i> 2000; <b>97</b>(8): 404651. <a target=xrefwindow id=d14871e5103 href="http://www.ncbi.nlm.nih.gov/pubmed/10759568">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5106 href="https://doi.org/10.1073/pnas.080536597">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5110 href="http://www.ncbi.nlm.nih.gov/pmc/articles/18143">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d14871e5120 class=n-a></a>Horie K, Tomida A, Sugimoto Y, <i> et al.</i>: SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin. <i>Oncogene.</i> 2002; <b>21</b>(52): 791322. <a target=xrefwindow id=d14871e5131 href="http://www.ncbi.nlm.nih.gov/pubmed/12439742">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5134 href="https://doi.org/10.1038/sj.onc.1205917">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d14871e5143 class=n-a></a>Cardellini E, Bramucci M, Gianfranceschi GL, <i> et al.</i>: Human topoisomerase I is phosphorylated <i>in vitro</i> on its amino terminal domain by protein kinase NII. <i>Biol Chem Hoppe Seyler.</i> 1994; <b>375</b>(4): 2559. <a target=xrefwindow id=d14871e5157 href="http://www.ncbi.nlm.nih.gov/pubmed/8060534">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5161 href="https://doi.org/10.1515/bchm3.1994.375.4.255">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d14871e5170 class=n-a></a>Hackbarth JS, Galvez-Peralta M, Dai NT, <i> et al.</i>: Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I. <i>J Biol Chem.</i> 2008; <b>283</b>(24): 1671122. <a target=xrefwindow id=d14871e5181 href="http://www.ncbi.nlm.nih.gov/pubmed/18408216">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5184 href="https://doi.org/10.1074/jbc.M802246200">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5188 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2423254">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d14871e5197 class=n-a></a>Bandyopadhyay K, Li P, Gjerset RA: CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity. <i>PLoS One.</i> 2012; <b>7</b>(11): e50427. <a target=xrefwindow id=d14871e5205 href="http://www.ncbi.nlm.nih.gov/pubmed/23185622">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5208 href="https://doi.org/10.1371/journal.pone.0050427">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5211 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3503890">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d14871e5220 class=n-a></a>Yang M, Hsu CT, Ting CY, <i> et al.</i>: Assembly of a polymeric chain of SUMO1 on human topoisomerase I <i>in vitro</i>. <i>J Biol Chem.</i> 2006; <b>281</b>(12): 826474. <a target=xrefwindow id=d14871e5234 href="http://www.ncbi.nlm.nih.gov/pubmed/16428803">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5238 href="https://doi.org/10.1074/jbc.M510364200">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d14871e5247 class=n-a></a>Jacquiau HR, van Waardenburg RC, Reid RJ, <i> et al.</i>: Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage. <i>J Biol Chem.</i> 2005; <b>280</b>(25): 2356675. <a target=xrefwindow id=d14871e5258 href="http://www.ncbi.nlm.nih.gov/pubmed/15817450">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5261 href="https://doi.org/10.1074/jbc.M500947200">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d14871e5271 class=n-a></a>van Waardenburg RC, Duda DM, Lancaster CS, <i> et al.</i>: Distinct functional domains of Ubc9 dictate cell survival and resistance to genotoxic stress. <i>Mol Cell Biol.</i> 2006; <b>26</b>(13): 495869. <a target=xrefwindow id=d14871e5282 href="http://www.ncbi.nlm.nih.gov/pubmed/16782883">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5285 href="https://doi.org/10.1128/MCB.00160-06">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5289 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1489148">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d14871e5298 class=n-a></a>Wright CM, Whitaker RH, Onuiri JE, <i> et al.</i>: UBC9 Mutant Reveals the Impact of Protein Dynamics on Substrate Selectivity and SUMO Chain Linkages. <i>Biochemistry.</i> 2019; <b>58</b>(6): 621632. <a target=xrefwindow id=d14871e5309 href="http://www.ncbi.nlm.nih.gov/pubmed/30574775">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5312 href="https://doi.org/10.1021/acs.biochem.8b01045">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5316 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6690184">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d14871e5325 class=n-a></a>Balakirev MY, Mullally JE, Favier A, <i> et al.</i>: Wss1 metalloprotease partners with Cdc48/Doa1 in processing genotoxic SUMO conjugates. <i>eLife.</i> 2015; <b>4</b>: e06763. <a target=xrefwindow id=d14871e5336 href="http://www.ncbi.nlm.nih.gov/pubmed/26349035">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5339 href="https://doi.org/10.7554/eLife.06763">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5343 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4559962">Free Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d14871e5352 class=n-a></a>Lopez-Mosqueda J, Maddi K, Prgomet S, <i> et al.</i>: SPRTN is a mammalian DNA-binding metalloprotease that resolves DNA-protein crosslinks. <i>eLife.</i> 2016; <b>5</b>: pii: e21491. <a target=xrefwindow id=d14871e5363 href="http://www.ncbi.nlm.nih.gov/pubmed/27852435">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5366 href="https://doi.org/10.7554/eLife.21491">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5370 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5127644">Free Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735406376"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e5379 class=n-a></a>Borgermann N, Ackermann L, Schwertman P, <i> et al.</i>: SUMOylation promotes protective responses to DNA-protein crosslinks. <i>EMBO J.</i> 2019; <b>38</b>(8): pii: e101496. <a target=xrefwindow id=d14871e5390 href="http://www.ncbi.nlm.nih.gov/pubmed/30914427">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5393 href="https://doi.org/10.15252/embj.2019101496">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5397 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6463212">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735406376">F1000 Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1002473"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e5411 class=n-a></a>Mao Y, Desai SD, Ting CY, <i> et al.</i>: 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. <i>J Biol Chem.</i> 2001; <b>276</b>(44): 406528. <a target=xrefwindow id=d14871e5422 href="http://www.ncbi.nlm.nih.gov/pubmed/11546768">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5425 href="https://doi.org/10.1074/jbc.M104009200">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1002473">F1000 Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d14871e5440 class=n-a></a>Hoa NN, Shimizu T, Zhou ZW, <i> et al.</i>: Mre11 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage Complexes. <i>Mol Cell.</i> 2016; <b>64</b>(3): 580592. <a target=xrefwindow id=d14871e5451 href="http://www.ncbi.nlm.nih.gov/pubmed/27814490">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5454 href="https://doi.org/10.1016/j.molcel.2016.10.011">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d14871e5463 class=n-a></a>Aparicio T, Baer R, Gottesman M, <i> et al.</i>: MRN, CtIP, and BRCA1 mediate repair of topoisomerase II-DNA adducts. <i>J Cell Biol.</i> 2016; <b>212</b>(4): 399408. <a target=xrefwindow id=d14871e5474 href="http://www.ncbi.nlm.nih.gov/pubmed/26880199">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5477 href="https://doi.org/10.1083/jcb.201504005">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5481 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4754713">Free Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d14871e5490 class=n-a></a>Nitiss KC, Malik M, He X, <i> et al.</i>: Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage. <i>Proc Natl Acad Sci U S A.</i> 2006; <b>103</b>(24): 89538. <a target=xrefwindow id=d14871e5501 href="http://www.ncbi.nlm.nih.gov/pubmed/16751265">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5504 href="https://doi.org/10.1073/pnas.0603455103">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5508 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1482547">Free Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d14871e5517 class=n-a></a>Murai J, Huang SY, Das BB, <i> et al.</i>: Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells. <i>J Biol Chem.</i> 2012; <b>287</b>(16): 1284857. <a target=xrefwindow id=d14871e5528 href="http://www.ncbi.nlm.nih.gov/pubmed/22375014">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5531 href="https://doi.org/10.1074/jbc.M111.333963">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5535 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3339927">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d14871e5544 class=n-a></a>Schellenberg MJ, Perera L, Strom CN, <i> et al.</i>: Reversal of DNA damage induced Topoisomerase 2 DNA-protein crosslinks by Tdp2. <i>Nucleic Acids Res.</i> 2016; <b>44</b>(8): 382944. <a target=xrefwindow id=d14871e5555 href="http://www.ncbi.nlm.nih.gov/pubmed/27060144">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5558 href="https://doi.org/10.1093/nar/gkw228">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5562 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4857006">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731185215"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e5571 class=n-a></a>Schellenberg MJ, Lieberman JA, Herrero-Ruiz A, <i> et al.</i>: ZATT (ZNF451)-mediated resolution of topoisomerase 2 DNA-protein cross-links. <i>Science.</i> 2017; <b>357</b>(6358): 14121416. <a target=xrefwindow id=d14871e5582 href="http://www.ncbi.nlm.nih.gov/pubmed/28912134">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5585 href="https://doi.org/10.1126/science.aam6468">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5589 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5623066">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731185215">F1000 Recommendation</a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727663513"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e5604 class=n-a></a>Wei Y, Diao LX, Lu S, <i> et al.</i>: SUMO-Targeted DNA Translocase Rrp2 Protects the Genome from Top2-Induced DNA Damage. <i>Mol Cell.</i> 2017; <b>66</b>(5): 581596.e6. <a target=xrefwindow id=d14871e5615 href="http://www.ncbi.nlm.nih.gov/pubmed/28552615">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5618 href="https://doi.org/10.1016/j.molcel.2017.04.017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727663513">F1000 Recommendation</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727717333"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e5632 class=n-a></a>Emanuelli A, Borroni AP, Apel-Sarid L, <i> et al.</i>: Smurf2-Mediated Stabilization of DNA Topoisomerase II Controls Genomic Integrity. <i>Cancer Res.</i> 2017; <b>77</b>(16): 42174227. <a target=xrefwindow id=d14871e5643 href="http://www.ncbi.nlm.nih.gov/pubmed/28611047">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5646 href="https://doi.org/10.1158/0008-5472.CAN-16-2828">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727717333">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d14871e5660 class=n-a></a>Houghton PJ, Cheshire PJ, Hallman JD 2nd, <i> et al.</i>: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. <i>Cancer Chemother Pharmacol.</i> 1995; <b>36</b>(5): 393403. <a target=xrefwindow id=d14871e5671 href="http://www.ncbi.nlm.nih.gov/pubmed/7634381">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5674 href="https://doi.org/10.1007/BF00686188">Publisher Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d14871e5683 class=n-a></a>Wagner LM: Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? <i>Clin Sarcoma Res.</i> 2015; <b>5</b>: 20. <a target=xrefwindow id=d14871e5691 href="http://www.ncbi.nlm.nih.gov/pubmed/26322224">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5694 href="https://doi.org/10.1186/s13569-015-0035-x">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5697 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4552408">Free Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d14871e5706 class=n-a></a>Hainsworth JD, Johnson DH, Frazier SR, <i> et al.</i>: Chronic daily administration of oral etoposide in refractory lymphoma. <i>Eur J Cancer.</i> 1990; <b>26</b>(7): 81821. <a target=xrefwindow id=d14871e5717 href="http://www.ncbi.nlm.nih.gov/pubmed/2145902">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5720 href="https://doi.org/10.1016/0277-5379(90)90160-u">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736613832"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e5729 class=n-a></a>You F, Gao C: Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy. <i>Curr Top Med Chem.</i> 2019; <b>19</b>(9): 713729. <a target=xrefwindow id=d14871e5737 href="http://www.ncbi.nlm.nih.gov/pubmed/30931860">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5740 href="https://doi.org/10.2174/1568026619666190401112948">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736613832">F1000 Recommendation</a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d14871e5755 class=n-a></a>Beretta GL, Zuco V, Perego P, <i> et al.</i>: Targeting DNA topoisomerase I with non-camptothecin poisons. <i>Curr Med Chem.</i> 2012; <b>19</b>(8): 123857. <a target=xrefwindow id=d14871e5766 href="http://www.ncbi.nlm.nih.gov/pubmed/22204335">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5769 href="https://doi.org/10.2174/092986712799320529">Publisher Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d14871e5778 class=n-a></a>Pommier Y, Cushman M, Doroshow JH: Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins. <i>Oncotarget.</i> 2018; <b>9</b>(99): 3728637288. <a target=xrefwindow id=d14871e5786 href="http://www.ncbi.nlm.nih.gov/pubmed/30647868">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5789 href="https://doi.org/10.18632/oncotarget.26466">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5792 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6324668">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733721497"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e5801 class=n-a></a>Burton JH, Mazcko C, LeBlanc A, <i> et al.</i>: NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. <i>Clin Cancer Res.</i> 2018; <b>24</b>(23): 58305840. <a target=xrefwindow id=d14871e5812 href="http://www.ncbi.nlm.nih.gov/pubmed/30061364">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5815 href="https://doi.org/10.1158/1078-0432.CCR-18-1498">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5819 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6312717">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733721497">F1000 Recommendation</a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d14871e5833 class=n-a></a>Drummond DC, Noble CO, Guo Z, <i> et al.</i>: Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. <i>Cancer Res.</i> 2006; <b>66</b>(6): 32717. <a target=xrefwindow id=d14871e5844 href="http://www.ncbi.nlm.nih.gov/pubmed/16540680">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5847 href="https://doi.org/10.1158/0008-5472.CAN-05-4007">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d14871e5856 class=n-a></a>Perez EA, Awada A, O'Shaughnessy J, <i> et al.</i>: Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(15): 15561568. <a target=xrefwindow id=d14871e5867 href="http://www.ncbi.nlm.nih.gov/pubmed/26482278">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5870 href="https://doi.org/10.1016/S1470-2045(15)00332-0">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d14871e5879 class=n-a></a>Rustin G, Vergote I, Micha JP, <i> et al.</i>: A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer. <i>Gynecol Oncol.</i> 2017; <b>147</b>(2): 276282. <a target=xrefwindow id=d14871e5890 href="http://www.ncbi.nlm.nih.gov/pubmed/28935273">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5893 href="https://doi.org/10.1016/j.ygyno.2017.08.026">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d14871e5903 class=n-a></a>Santi DV, Schneider EL, Ashley GW: Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation. <i>J Med Chem.</i> 2014; <b>57</b>(6): 230314. <a target=xrefwindow id=d14871e5911 href="http://www.ncbi.nlm.nih.gov/pubmed/24494988">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5914 href="https://doi.org/10.1021/jm401644v">Publisher Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736613833"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e5923 class=n-a></a>Chernov L, Deyell RJ, Anantha M, <i> et al.</i>: Optimization of liposomal topotecan for use in treating neuroblastoma. <i>Cancer Med.</i> 2017; <b>6</b>(6): 12401254. <a target=xrefwindow id=d14871e5934 href="http://www.ncbi.nlm.nih.gov/pubmed/28544814">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5937 href="https://doi.org/10.1002/cam4.1083">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5941 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5463073">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736613833">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d14871e5955 class=n-a></a>Golombek SK, May JN, Theek B, <i> et al.</i>: Tumor targeting via EPR: Strategies to enhance patient responses. <i>Adv Drug Deliv Rev.</i> 2018; <b>130</b>: 1738. <a target=xrefwindow id=d14871e5966 href="http://www.ncbi.nlm.nih.gov/pubmed/30009886">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5969 href="https://doi.org/10.1016/j.addr.2018.07.007">Publisher Full Text </a> | <a target=xrefwindow id=d14871e5973 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6130746">Free Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d14871e5982 class=n-a></a>Ogitani Y, Aida T, Hagihara K, <i> et al.</i>: DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. <i>Clin Cancer Res.</i> 2016; <b>22</b>(20): 50975108. <a target=xrefwindow id=d14871e5993 href="http://www.ncbi.nlm.nih.gov/pubmed/27026201">PubMed Abstract </a> | <a target=xrefwindow id=d14871e5996 href="https://doi.org/10.1158/1078-0432.CCR-15-2822">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d14871e6005 class=n-a></a>Nakada T, Sugihara K, Jikoh T, <i> et al.</i>: The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. <i>Chem Pharm Bull (Tokyo).</i> 2019; <b>67</b>(3): 173185. <a target=xrefwindow id=d14871e6016 href="http://www.ncbi.nlm.nih.gov/pubmed/30827997">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6019 href="https://doi.org/10.1248/cpb.c18-00744">Publisher Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735680777"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e6028 class=n-a></a>Tamura K, Tsurutani J, Takahashi S, <i> et al.</i>: Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. <i>Lancet Oncol.</i> 2019; <b>20</b>(6): 816826. <a target=xrefwindow id=d14871e6039 href="http://www.ncbi.nlm.nih.gov/pubmed/31047803">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6042 href="https://doi.org/10.1016/S1470-2045(19)30097-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735680777">F1000 Recommendation</a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735680776"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e6057 class=n-a></a>Shitara K, Iwata H, Takahashi S, <i> et al.</i>: Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. <i>Lancet Oncol.</i> 2019; <b>20</b>(6): 827836. <a target=xrefwindow id=d14871e6068 href="http://www.ncbi.nlm.nih.gov/pubmed/31047804">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6071 href="https://doi.org/10.1016/S1470-2045(19)30088-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735680776">F1000 Recommendation</a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d14871e6085 class=n-a></a>Heske CM, Mendoza A, Edessa LD, <i> et al.</i>: STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma. <i>Oncotarget.</i> 2016; <b>7</b>(40): 6554065552. <a target=xrefwindow id=d14871e6096 href="http://www.ncbi.nlm.nih.gov/pubmed/27608846">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6099 href="https://doi.org/10.18632/oncotarget.11869">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6103 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5323173">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d14871e6112 class=n-a></a>Gaponova AV, Nikonova AS, Deneka A, <i> et al.</i>: A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer. <i>Clin Cancer Res.</i> 2016; <b>22</b>(20): 51205129. <a target=xrefwindow id=d14871e6123 href="http://www.ncbi.nlm.nih.gov/pubmed/27267850">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6126 href="https://doi.org/10.1158/1078-0432.CCR-15-3068">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6130 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5065742">Free Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d14871e6139 class=n-a></a>Gokduman K: Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes. <i>Curr Drug Targets.</i> 2016; <b>17</b>(16): 19281939. <a target=xrefwindow id=d14871e6147 href="http://www.ncbi.nlm.nih.gov/pubmed/27138759">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6150 href="https://doi.org/10.2174/1389450117666160502151707">Publisher Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d14871e6159 class=n-a></a>Elsayed MSA, Su Y, Wang P, <i> et al.</i>: Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I. <i>J Med Chem.</i> 2017; <b>60</b>(13): 53645376. <a target=xrefwindow id=d14871e6170 href="http://www.ncbi.nlm.nih.gov/pubmed/28657311">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6173 href="https://doi.org/10.1021/acs.jmedchem.6b01870">Publisher Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d14871e6182 class=n-a></a>Beck DE, Lv W, Abdelmalak M, <i> et al.</i>: Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons. <i>Bioorg Med Chem.</i> 2016; <b>24</b>(7): 146979. <a target=xrefwindow id=d14871e6193 href="http://www.ncbi.nlm.nih.gov/pubmed/26906474">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6196 href="https://doi.org/10.1016/j.bmc.2016.02.015">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6200 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4789169">Free Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d14871e6210 class=n-a></a>Marzi L, Agama K, Murai J, <i> et al.</i>: Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. <i>Mol Cancer Ther.</i> 2018; <b>17</b>(8): 16941704. <a target=xrefwindow id=d14871e6221 href="http://www.ncbi.nlm.nih.gov/pubmed/29748210">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6224 href="https://doi.org/10.1158/1535-7163.MCT-18-0028">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6228 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6072611">Free Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733126683"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e6237 class=n-a></a>Iwata TN, Ishii C, Ishida S, <i> et al.</i>: A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. <i>Mol Cancer Ther.</i> 2018; <b>17</b>(7): 14941503. <a target=xrefwindow id=d14871e6248 href="http://www.ncbi.nlm.nih.gov/pubmed/29703841">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6251 href="https://doi.org/10.1158/1535-7163.MCT-17-0749">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733126683">F1000 Recommendation</a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d14871e6265 class=n-a></a>Yonesaka K, Takegawa N, Watanabe S, <i> et al.</i>: An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. <i>Oncogene.</i> 2019; <b>38</b>(9): 13981409. <a target=xrefwindow id=d14871e6276 href="http://www.ncbi.nlm.nih.gov/pubmed/30302022">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6279 href="https://doi.org/10.1038/s41388-018-0517-4">Publisher Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d14871e6288 class=n-a></a>Cardillo TM, Govindan SV, Sharkey RM, <i> et al.</i>: Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. <i>Clin Cancer Res.</i> 2011; <b>17</b>(10): 315769. <a target=xrefwindow id=d14871e6299 href="http://www.ncbi.nlm.nih.gov/pubmed/21372224">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6302 href="https://doi.org/10.1158/1078-0432.CCR-10-2939">Publisher Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d14871e6311 class=n-a></a>Sharkey RM, McBride WJ, Cardillo TM, <i> et al.</i>: Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). <i>Clin Cancer Res.</i> 2015; <b>21</b>(22): 51318. <a target=xrefwindow id=d14871e6322 href="http://www.ncbi.nlm.nih.gov/pubmed/26106073">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6325 href="https://doi.org/10.1158/1078-0432.CCR-15-0670">Publisher Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d14871e6334 class=n-a></a>Goldenberg DM, Sharkey RM: Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. <i>mAbs.</i> 2019; <b>11</b>(6): 987995. <a target=xrefwindow id=d14871e6342 href="http://www.ncbi.nlm.nih.gov/pubmed/31208270">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6345 href="https://doi.org/10.1080/19420862.2019.1632115">Publisher Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727407789"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e6355 class=n-a></a>Bardia A, Mayer IA, Diamond JR, <i> et al.</i>: Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>J Clin Oncol.</i> 2017; <b>35</b>(19): 21412148. <a target=xrefwindow id=d14871e6366 href="http://www.ncbi.nlm.nih.gov/pubmed/28291390">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6369 href="https://doi.org/10.1200/JCO.2016.70.8297">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6373 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5559902">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727407789">F1000 Recommendation</a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735124171"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e6387 class=n-a></a>Bardia A, Mayer IA, Vahdat LT, <i> et al.</i>: Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. <i>N Engl J Med.</i> 2019; <b>380</b>(8): 741751. <a target=xrefwindow id=d14871e6398 href="http://www.ncbi.nlm.nih.gov/pubmed/30786188">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6401 href="https://doi.org/10.1056/NEJMoa1814213">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735124171">F1000 Recommendation</a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727655431"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e6415 class=n-a></a>Heist RS, Guarino MJ, Masters G, <i> et al.</i>: Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. <i>J Clin Oncol.</i> 2017; <b>35</b>(24): 27902797. <a target=xrefwindow id=d14871e6426 href="http://www.ncbi.nlm.nih.gov/pubmed/28548889">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6429 href="https://doi.org/10.1200/JCO.2016.72.1894">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727655431">F1000 Recommendation</a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727782010"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e6443 class=n-a></a>Gray JE, Heist RS, Starodub AN, <i> et al.</i>: Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. <i>Clin Cancer Res.</i> 2017; <b>23</b>(19): 57115719. <a target=xrefwindow id=d14871e6454 href="http://www.ncbi.nlm.nih.gov/pubmed/28679770">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6457 href="https://doi.org/10.1158/1078-0432.CCR-17-0933">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727782010">F1000 Recommendation</a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d14871e6471 class=n-a></a>Cardillo TM, Sharkey RM, Rossi DL, <i> et al.</i>: Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in <i>BRCA1/2</i>-wild-type Triple-Negative Breast Cancer. <i>Clin Cancer Res.</i> 2017; <b>23</b>(13): 34053415. <a target=xrefwindow id=d14871e6485 href="http://www.ncbi.nlm.nih.gov/pubmed/28069724">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6489 href="https://doi.org/10.1158/1078-0432.CCR-16-2401">Publisher Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d14871e6498 class=n-a></a>Du Y, Zhang W, He R, <i> et al.</i>: Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with <i>in vitro</i> anticancer effects. <i>Bioorg Med Chem.</i> 2017; <b>25</b>(12): 32473258. <a target=xrefwindow id=d14871e6512 href="http://www.ncbi.nlm.nih.gov/pubmed/28465086">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6516 href="https://doi.org/10.1016/j.bmc.2017.04.025">Publisher Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d14871e6526 class=n-a></a>Chae S, Kim D, Lee KJ, <i> et al.</i>: Encapsulation and Enhanced Delivery of Topoisomerase I Inhibitors in Functionalized Carbon Nanotubes. <i>ACS Omega.</i> 2018; <b>3</b>(6): 59385945. <a target=xrefwindow id=d14871e6537 href="http://www.ncbi.nlm.nih.gov/pubmed/30023933">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6540 href="https://doi.org/10.1021/acsomega.8b00399">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6544 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6044808">Free Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d14871e6553 class=n-a></a>Gigliotti CL, Minelli R, Cavalli R, <i> et al.</i>: <i>In Vitro</i> and <i>In Vivo</i> Therapeutic Evaluation of Camptothecin-Encapsulated <i></i>-Cyclodextrin Nanosponges in Prostate Cancer. <i>J Biomed Nanotechnol.</i> 2016; <b>12</b>(1): 11427. <a target=xrefwindow id=d14871e6574 href="http://www.ncbi.nlm.nih.gov/pubmed/27301177">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6577 href="https://doi.org/10.1166/jbn.2016.2144">Publisher Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d14871e6586 class=n-a></a>Gigliotti CL, Ferrara B, Occhipinti S, <i> et al.</i>: Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells <i>in vitro</i> and <i>in vivo</i> on orthotopic xenograft tumors. <i>Drug Deliv.</i> 2017; <b>24</b>(1): 670680. <a target=xrefwindow id=d14871e6604 href="http://www.ncbi.nlm.nih.gov/pubmed/28368209">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6607 href="https://doi.org/10.1080/10717544.2017.1303856">Publisher Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d14871e6616 class=n-a></a>Bombarde O, Larminat F, Gomez D, <i> et al.</i>: The DNA-Binding Polyamine Moiety in the Vectorized DNA Topoisomerase II Inhibitor F14512 Alters Reparability of the Consequent Enzyme-Linked DNA Double-Strand Breaks. <i>Mol Cancer Ther.</i> 2017; <b>16</b>(10): 21662177. <a target=xrefwindow id=d14871e6627 href="http://www.ncbi.nlm.nih.gov/pubmed/28611105">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6630 href="https://doi.org/10.1158/1535-7163.MCT-16-0767">Publisher Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d14871e6639 class=n-a></a>Leary A, Le Tourneau C, Varga A, <i> et al.</i>: Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer. <i>Invest New Drugs.</i> 2019; <b>37</b>(4): 693701. <a target=xrefwindow id=d14871e6650 href="http://www.ncbi.nlm.nih.gov/pubmed/30547316">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6653 href="https://doi.org/10.1007/s10637-018-0688-4">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6657 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6647401">Free Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d14871e6666 class=n-a></a>Hasinoff BB, Wu X, Patel D, <i> et al.</i>: Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase II Isoform. <i>J Pharmacol Exp Ther.</i> 2016; <b>356</b>(2): 397409. <a target=xrefwindow id=d14871e6677 href="http://www.ncbi.nlm.nih.gov/pubmed/26660439">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6680 href="https://doi.org/10.1124/jpet.115.228650">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6684 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4746493">Free Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d14871e6694 class=n-a></a>Sedov V, Stuart RK: Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape. <i>Ther Adv Hematol.</i> 2017; <b>8</b>(6): 185195. <a target=xrefwindow id=d14871e6702 href="http://www.ncbi.nlm.nih.gov/pubmed/28567238">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6705 href="https://doi.org/10.1177/2040620717703012">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6708 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5424861">Free Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d14871e6717 class=n-a></a>Blower TR, Bandak A, Lee ASY, <i> et al.</i>: A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents. <i>Nucleic Acids Res.</i> 2019; <b>47</b>(15): 81638179. <a target=xrefwindow id=d14871e6728 href="http://www.ncbi.nlm.nih.gov/pubmed/31287876">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6731 href="https://doi.org/10.1093/nar/gkz579">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6735 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6735899">Free Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732674772"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e6744 class=n-a></a>Infante Lara L, Fenner S, Ratcliffe S, <i> et al.</i>: Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences. <i>Nucleic Acids Res.</i> 2018; <b>46</b>(5): 22182233. <a target=xrefwindow id=d14871e6755 href="http://www.ncbi.nlm.nih.gov/pubmed/29447373">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6758 href="https://doi.org/10.1093/nar/gky072">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6762 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5861436">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732674772">F1000 Recommendation</a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/720490936"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e6776 class=n-a></a>Wahlberg E, Karlberg T, Kouznetsova E, <i> et al.</i>: Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. <i>Nat Biotechnol.</i> 2012; <b>30</b>(3): 2838. <a target=xrefwindow id=d14871e6787 href="http://www.ncbi.nlm.nih.gov/pubmed/22343925">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6790 href="https://doi.org/10.1038/nbt.2121">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/720490936">F1000 Recommendation</a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a name=d14871e6804 class=n-a></a>Scott CL, Swisher EM, Kaufmann SH: Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. <i>J Clin Oncol.</i> 2015; <b>33</b>(12): 1397406. <a target=xrefwindow id=d14871e6812 href="http://www.ncbi.nlm.nih.gov/pubmed/25779564">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6815 href="https://doi.org/10.1200/JCO.2014.58.8848">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6818 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4517072">Free Full Text </a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d14871e6827 class=n-a></a>Konstantinopoulos PA, Ceccaldi R, Shapiro GI, <i> et al.</i>: Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. <i>Cancer Discov.</i> 2015; <b>5</b>(11): 113754. <a target=xrefwindow id=d14871e6838 href="http://www.ncbi.nlm.nih.gov/pubmed/26463832">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6841 href="https://doi.org/10.1158/2159-8290.CD-15-0714">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6845 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4631624">Free Full Text </a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d14871e6855 class=n-a></a>Feng FY, de Bono JS, Rubin MA, <i> et al.</i>: Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. <i>Mol Cell.</i> 2015; <b>58</b>(6): 92534. <a target=xrefwindow id=d14871e6866 href="http://www.ncbi.nlm.nih.gov/pubmed/26091341">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6869 href="https://doi.org/10.1016/j.molcel.2015.04.016">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6873 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4487541">Free Full Text </a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d14871e6882 class=n-a></a>del Rivero J, Kohn EC: PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies. <i>Oncology (Williston Park).</i> 2017; <b>31</b>(4): 26573. <a target=xrefwindow id=d14871e6890 href="http://www.ncbi.nlm.nih.gov/pubmed/28412778">PubMed Abstract </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d14871e6899 class=n-a></a>Shackleford GM, Varmus HE: Construction of a clonable, infectious, and tumorigenic mouse mammary tumor virus provirus and a derivative genetic vector. <i>Proc Natl Acad Sci U S A.</i> 1988; <b>85</b>(24): 96559. <a target=xrefwindow id=d14871e6907 href="http://www.ncbi.nlm.nih.gov/pubmed/2849114">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6910 href="https://doi.org/10.1073/pnas.85.24.9655">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6913 href="http://www.ncbi.nlm.nih.gov/pmc/articles/282828">Free Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726562054"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e6922 class=n-a></a>Ray Chaudhuri A, Callen E, Ding X, <i> et al.</i>: Replication fork stability confers chemoresistance in BRCA-deficient cells. <i>Nature.</i> 2016; <b>535</b>(7612): 3827. <a target=xrefwindow id=d14871e6933 href="http://www.ncbi.nlm.nih.gov/pubmed/27443740">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6936 href="https://doi.org/10.1038/nature18325">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6940 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4959813">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726562054">F1000 Recommendation</a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717993387"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e6954 class=n-a></a>Berti M, Ray Chaudhuri A, Thangavel S, <i> et al.</i>: Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition. <i>Nat Struct Mol Biol.</i> 2013; <b>20</b>(3): 34754. <a target=xrefwindow id=d14871e6965 href="http://www.ncbi.nlm.nih.gov/pubmed/23396353">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6968 href="https://doi.org/10.1038/nsmb.2501">Publisher Full Text </a> | <a target=xrefwindow id=d14871e6972 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3897332">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717993387">F1000 Recommendation</a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726116732"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e6986 class=n-a></a>Berti M, Vindigni A: Replication stress: getting back on track. <i>Nat Struct Mol Biol.</i> 2016; <b>23</b>(2): 1039. <a target=xrefwindow id=d14871e6994 href="http://www.ncbi.nlm.nih.gov/pubmed/26840898">PubMed Abstract </a> | <a target=xrefwindow id=d14871e6997 href="https://doi.org/10.1038/nsmb.3163">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7000 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5125612">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726116732">F1000 Recommendation</a></span></li><li><a name=ref-162 class=n-a></a><span class=label>162. </span>&nbsp;<span class=citation><a name=d14871e7015 class=n-a></a>Bryant HE, Petermann E, Schultz N, <i> et al.</i>: PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. <i>EMBO J.</i> 2009; <b>28</b>(17): 260115. <a target=xrefwindow id=d14871e7026 href="http://www.ncbi.nlm.nih.gov/pubmed/19629035">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7029 href="https://doi.org/10.1038/emboj.2009.206">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7033 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2738702">Free Full Text </a></span></li><li><a name=ref-163 class=n-a></a><span class=label>163. </span>&nbsp;<span class=citation><a name=d14871e7042 class=n-a></a>Malanga M, Althaus FR: Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and Induces DNA strand break resealing. <i>J Biol Chem.</i> 2004; <b>279</b>(7): 52448. <a target=xrefwindow id=d14871e7050 href="http://www.ncbi.nlm.nih.gov/pubmed/14699148">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7053 href="https://doi.org/10.1074/jbc.C300437200">Publisher Full Text </a></span></li><li><a name=ref-164 class=n-a></a><span class=label>164. </span>&nbsp;<span class=citation><a name=d14871e7062 class=n-a></a>Bowman KJ, White A, Golding BT, <i> et al.</i>: Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. <i>Br J Cancer.</i> 1998; <b>78</b>(10): 126977. <a target=xrefwindow id=d14871e7073 href="http://www.ncbi.nlm.nih.gov/pubmed/9823965">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7076 href="https://doi.org/10.1038/bjc.1998.670">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7080 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2063197">Free Full Text </a></span></li><li><a name=ref-165 class=n-a></a><span class=label>165. </span>&nbsp;<span class=citation><a name=d14871e7089 class=n-a></a>Satoh MS, Lindahl T: Role of poly(ADP-ribose) formation in DNA repair. <i>Nature.</i> 1992; <b>356</b>(6367): 3568. <a target=xrefwindow id=d14871e7097 href="http://www.ncbi.nlm.nih.gov/pubmed/1549180">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7100 href="https://doi.org/10.1038/356356a0">Publisher Full Text </a></span></li><li><a name=ref-166 class=n-a></a><span class=label>166. </span>&nbsp;<span class=citation><a name=d14871e7109 class=n-a></a>Satoh MS, Poirier GG, Lindahl T: Dual function for poly(ADP-ribose) synthesis in response to DNA strand breakage. <i>Biochemistry.</i> 1994; <b>33</b>(23): 7099106. <a target=xrefwindow id=d14871e7117 href="http://www.ncbi.nlm.nih.gov/pubmed/8003475">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7120 href="https://doi.org/10.1021/bi00189a012">Publisher Full Text </a></span></li><li><a name=ref-167 class=n-a></a><span class=label>167. </span>&nbsp;<span class=citation><a name=d14871e7129 class=n-a></a>Patel AG, Flatten KS, Schneider PA, <i> et al.</i>: Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. <i>J Biol Chem.</i> 2012; <b>287</b>(6): 4198210. <a target=xrefwindow id=d14871e7140 href="http://www.ncbi.nlm.nih.gov/pubmed/22158865">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7143 href="https://doi.org/10.1074/jbc.M111.296475">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7147 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3281688">Free Full Text </a></span></li><li><a name=ref-168 class=n-a></a><span class=label>168. </span>&nbsp;<span class=citation><a name=d14871e7157 class=n-a></a>Calabrese CR, Almassy R, Barton S, <i> et al.</i>: Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. <i>J Natl Cancer Inst.</i> 2004; <b>96</b>(1): 5667. <a target=xrefwindow id=d14871e7168 href="http://www.ncbi.nlm.nih.gov/pubmed/14709739">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7171 href="https://doi.org/10.1093/jnci/djh005">Publisher Full Text </a></span></li><li><a name=ref-169 class=n-a></a><span class=label>169. </span>&nbsp;<span class=citation><a name=d14871e7180 class=n-a></a>Daniel RA, Rozanska AL, Thomas HD, <i> et al.</i>: Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. <i>Clin Cancer Res.</i> 2009; <b>15</b>(4): 12419. <a target=xrefwindow id=d14871e7191 href="http://www.ncbi.nlm.nih.gov/pubmed/19174487">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7194 href="https://doi.org/10.1158/1078-0432.CCR-08-1095">Publisher Full Text </a></span></li><li><a name=ref-170 class=n-a></a><span class=label>170. </span>&nbsp;<span class=citation><a name=d14871e7203 class=n-a></a>Slichenmyer WJ, Rowinsky EK, Donehower RC, <i> et al.</i>: The current status of camptothecin analogues as antitumor agents. <i>J Natl Cancer Inst.</i> 1993; <b>85</b>(4): 27191. <a target=xrefwindow id=d14871e7214 href="http://www.ncbi.nlm.nih.gov/pubmed/8381186">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7217 href="https://doi.org/10.1093/jnci/85.4.271">Publisher Full Text </a></span></li><li><a name=ref-171 class=n-a></a><span class=label>171. </span>&nbsp;<span class=citation><a name=d14871e7226 class=n-a></a>Hopkins TA, Ainsworth WB, Ellis PA, <i> et al.</i>: PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow. <i>Mol Cancer Res.</i> 2019; <b>17</b>(2): 409419. <a target=xrefwindow id=d14871e7237 href="http://www.ncbi.nlm.nih.gov/pubmed/30429212">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7240 href="https://doi.org/10.1158/1541-7786.MCR-18-0138">Publisher Full Text </a></span></li><li><a name=ref-172 class=n-a></a><span class=label>172. </span>&nbsp;<span class=citation><a name=d14871e7249 class=n-a></a>Rowinsky EK: Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule? <i>Oncologist.</i> 2002; <b>7</b>(4): 32430. <a target=xrefwindow id=d14871e7257 href="http://www.ncbi.nlm.nih.gov/pubmed/12185294">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7260 href="https://doi.org/10.1634/theoncologist.7-4-324">Publisher Full Text </a></span></li><li><a name=ref-173 class=n-a></a><span class=label>173. </span>&nbsp;<span class=citation><a name=d14871e7269 class=n-a></a>Wahner Hendrickson AE, Menefee ME, Hartmann LC, <i> et al.</i>: A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. <i>Clin Cancer Res.</i> 2018; <b>24</b>(4): 744752. <a target=xrefwindow id=d14871e7280 href="http://www.ncbi.nlm.nih.gov/pubmed/29138343">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7283 href="https://doi.org/10.1158/1078-0432.CCR-17-1590">Publisher Full Text </a></span></li><li><a name=ref-174 class=n-a></a><span class=label>174. </span>&nbsp;<span class=citation><a name=d14871e7293 class=n-a></a>Ciccia A, Elledge SJ: The DNA damage response: making it safe to play with knives. <i>Mol Cell.</i> 2010; <b>40</b>(2): 179204. <a target=xrefwindow id=d14871e7301 href="http://www.ncbi.nlm.nih.gov/pubmed/20965415">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7304 href="https://doi.org/10.1016/j.molcel.2010.09.019">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7307 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2988877">Free Full Text </a></span></li><li><a name=ref-175 class=n-a></a><span class=label>175. </span>&nbsp;<span class=citation><a name=d14871e7316 class=n-a></a>Karnitz LM, Zou L: Molecular Pathways: Targeting ATR in Cancer Therapy. <i>Clin Cancer Res.</i> 2015; <b>21</b>(21): 47805. <a target=xrefwindow id=d14871e7324 href="http://www.ncbi.nlm.nih.gov/pubmed/26362996">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7327 href="https://doi.org/10.1158/1078-0432.CCR-15-0479">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7330 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4631635">Free Full Text </a></span></li><li><a name=ref-176 class=n-a></a><span class=label>176. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/728649753"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e7339 class=n-a></a>Saldivar JC, Cortez D, Cimprich KA: The essential kinase ATR: ensuring faithful duplication of a challenging genome. <i>Nat Rev Mol Cell Biol.</i> 2017; <b>18</b>(10): 622636. <a target=xrefwindow id=d14871e7347 href="http://www.ncbi.nlm.nih.gov/pubmed/28811666">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7350 href="https://doi.org/10.1038/nrm.2017.67">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7353 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5796526">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/728649753">F1000 Recommendation</a></span></li><li><a name=ref-177 class=n-a></a><span class=label>177. </span>&nbsp;<span class=citation><a name=d14871e7367 class=n-a></a>Loegering D, Arlander SJ, Hackbarth J, <i> et al.</i>: Rad9 protects cells from topoisomerase poison-induced cell death. <i>J Biol Chem.</i> 2004; <b>279</b>(18): 186417. <a target=xrefwindow id=d14871e7378 href="http://www.ncbi.nlm.nih.gov/pubmed/14988409">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7381 href="https://doi.org/10.1074/jbc.M313536200">Publisher Full Text </a></span></li><li><a name=ref-178 class=n-a></a><span class=label>178. </span>&nbsp;<span class=citation><a name=d14871e7390 class=n-a></a>Flatten K, Dai NT, Vroman BT, <i> et al.</i>: The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. <i>J Biol Chem.</i> 2005; <b>280</b>(14): 1434955. <a target=xrefwindow id=d14871e7401 href="http://www.ncbi.nlm.nih.gov/pubmed/15699047">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7404 href="https://doi.org/10.1074/jbc.M411890200">Publisher Full Text </a></span></li><li><a name=ref-179 class=n-a></a><span class=label>179. </span>&nbsp;<span class=citation><a name=d14871e7413 class=n-a></a>Zabludoff SD, Deng C, Grondine MR, <i> et al.</i>: AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. <i>Mol Cancer Ther.</i> 2008; <b>7</b>(9): 295566. <a target=xrefwindow id=d14871e7424 href="http://www.ncbi.nlm.nih.gov/pubmed/18790776">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7427 href="https://doi.org/10.1158/1535-7163.MCT-08-0492">Publisher Full Text </a></span></li><li><a name=ref-180 class=n-a></a><span class=label>180. </span>&nbsp;<span class=citation><a name=d14871e7437 class=n-a></a>Ma CX, Cai S, Li S, <i> et al.</i>: Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. <i>J Clin Invest.</i> 2012; <b>122</b>(4): 154152. <a target=xrefwindow id=d14871e7448 href="http://www.ncbi.nlm.nih.gov/pubmed/22446188">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7451 href="https://doi.org/10.1172/JCI58765">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7455 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3314455">Free Full Text </a></span></li><li><a name=ref-181 class=n-a></a><span class=label>181. </span>&nbsp;<span class=citation><a name=d14871e7464 class=n-a></a>Montano R, Chung I, Garner KM, <i> et al.</i>: Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. <i>Mol Cancer Ther.</i> 2012; <b>11</b>(2): 42738. <a target=xrefwindow id=d14871e7475 href="http://www.ncbi.nlm.nih.gov/pubmed/22203733">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7478 href="https://doi.org/10.1158/1535-7163.MCT-11-0406">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7482 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3277678">Free Full Text </a></span></li><li><a name=ref-182 class=n-a></a><span class=label>182. </span>&nbsp;<span class=citation><a name=d14871e7491 class=n-a></a>Huntoon CJ, Flatten KS, Wahner Hendrickson AE, <i> et al.</i>: ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. <i>Cancer Res.</i> 2013; <b>73</b>(12): 368391. <a target=xrefwindow id=d14871e7502 href="http://www.ncbi.nlm.nih.gov/pubmed/23548269">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7505 href="https://doi.org/10.1158/0008-5472.CAN-13-0110">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7509 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3687010">Free Full Text </a></span></li><li><a name=ref-183 class=n-a></a><span class=label>183. </span>&nbsp;<span class=citation><a name=d14871e7518 class=n-a></a>Joss R, Martin SE, Guha R, <i> et al.</i>: ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. <i>Cancer Res.</i> 2014; <b>74</b>(23): 696879. <a target=xrefwindow id=d14871e7529 href="http://www.ncbi.nlm.nih.gov/pubmed/25269479">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7532 href="https://doi.org/10.1158/0008-5472.CAN-13-3369">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7536 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4252598">Free Full Text </a></span></li><li><a name=ref-184 class=n-a></a><span class=label>184. </span>&nbsp;<span class=citation><a name=d14871e7545 class=n-a></a>Ho AL, Bendell JC, Cleary JM, <i> et al.</i>: Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors. <i>JCO.</i> 2011; <b>29</b>(15_suppl): 3033. <a target=xrefwindow id=d14871e7556 href="https://doi.org/10.1200/jco.2011.29.15_suppl.3033">Publisher Full Text </a></span></li><li><a name=ref-185 class=n-a></a><span class=label>185. </span>&nbsp;<span class=citation><a name=d14871e7565 class=n-a></a>Sausville E, Lorusso P, Carducci M, <i> et al.</i>: Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. <i>Cancer Chemother Pharmacol.</i> 2014; <b>73</b>(3): 53949. <a target=xrefwindow id=d14871e7576 href="http://www.ncbi.nlm.nih.gov/pubmed/24448638">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7579 href="https://doi.org/10.1007/s00280-014-2380-5">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7583 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4486055">Free Full Text </a></span></li><li><a name=ref-186 class=n-a></a><span class=label>186. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727254915"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e7593 class=n-a></a>Min A, Im SA, Jang H, <i> et al.</i>: AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. <i>Mol Cancer Ther.</i> 2017; <b>16</b>(4): 566577. <a target=xrefwindow id=d14871e7604 href="http://www.ncbi.nlm.nih.gov/pubmed/28138034">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7607 href="https://doi.org/10.1158/1535-7163.MCT-16-0378">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727254915">F1000 Recommendation</a></span></li><li><a name=ref-187 class=n-a></a><span class=label>187. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735738721"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e7621 class=n-a></a>Knegtel R, Charrier JD, Durrant S, <i> et al.</i>: Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor. <i>J Med Chem.</i> 2019; <b>62</b>(11): 55475561. <a target=xrefwindow id=d14871e7632 href="http://www.ncbi.nlm.nih.gov/pubmed/31074988">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7635 href="https://doi.org/10.1021/acs.jmedchem.9b00426">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735738721">F1000 Recommendation</a></span></li><li><a name=ref-188 class=n-a></a><span class=label>188. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732320460"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e7649 class=n-a></a>Thomas A, Redon CE, Sciuto L, <i> et al.</i>: Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. <i>J Clin Oncol.</i> 2018; <b>36</b>(16): 15941602. <a target=xrefwindow id=d14871e7660 href="http://www.ncbi.nlm.nih.gov/pubmed/29252124">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7663 href="https://doi.org/10.1200/JCO.2017.76.6915">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7667 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5978471">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732320460">F1000 Recommendation</a></span></li><li><a name=ref-189 class=n-a></a><span class=label>189. </span>&nbsp;<span class=citation><a name=d14871e7681 class=n-a></a>Topalian SL, Drake CG, Pardoll DM: Immune checkpoint blockade: a common denominator approach to cancer therapy. <i>Cancer Cell.</i> 2015; <b>27</b>(4): 45061. <a target=xrefwindow id=d14871e7689 href="http://www.ncbi.nlm.nih.gov/pubmed/25858804">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7692 href="https://doi.org/10.1016/j.ccell.2015.03.001">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7695 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4400238">Free Full Text </a></span></li><li><a name=ref-190 class=n-a></a><span class=label>190. </span>&nbsp;<span class=citation><a name=d14871e7704 class=n-a></a>Hoos A: Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. <i>Nat Rev Drug Discov.</i> 2016; <b>15</b>(4): 23547. <a target=xrefwindow id=d14871e7712 href="http://www.ncbi.nlm.nih.gov/pubmed/26965203">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7715 href="https://doi.org/10.1038/nrd.2015.35">Publisher Full Text </a></span></li><li><a name=ref-191 class=n-a></a><span class=label>191. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732995103"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e7724 class=n-a></a>Li T, Chen ZJ: The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. <i>J Exp Med.</i> 2018; <b>215</b>(5): 12871299. <a target=xrefwindow id=d14871e7732 href="http://www.ncbi.nlm.nih.gov/pubmed/29622565">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7735 href="https://doi.org/10.1084/jem.20180139">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7738 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5940270">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732995103">F1000 Recommendation</a></span></li><li><a name=ref-192 class=n-a></a><span class=label>192. </span>&nbsp;<span class=citation><a name=d14871e7753 class=n-a></a>Chen Q, Sun L, Chen ZJ: Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. <i>Nat Immunol.</i> 2016; <b>17</b>(10): 11429. <a target=xrefwindow id=d14871e7761 href="http://www.ncbi.nlm.nih.gov/pubmed/27648547">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7764 href="https://doi.org/10.1038/ni.3558">Publisher Full Text </a></span></li><li><a name=ref-193 class=n-a></a><span class=label>193. </span>&nbsp;<span class=citation><a name=d14871e7773 class=n-a></a>Berger G, Marloye M, Lawler SE: Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy. <i>Trends Mol Med.</i> 2019; <b>25</b>(5): 412427. <a target=xrefwindow id=d14871e7781 href="http://www.ncbi.nlm.nih.gov/pubmed/30885429">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7784 href="https://doi.org/10.1016/j.molmed.2019.02.007">Publisher Full Text </a></span></li><li><a name=ref-194 class=n-a></a><span class=label>194. </span>&nbsp;<span class=citation><a name=d14871e7793 class=n-a></a>Alfonsi R, Grassi L, Signore M, <i> et al.</i>: The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation. <i>Int J Mol Sci.</i> 2018; <b>19</b>(4): pii: E1183. <a target=xrefwindow id=d14871e7804 href="http://www.ncbi.nlm.nih.gov/pubmed/29652798">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7807 href="https://doi.org/10.3390/ijms19041183">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7811 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5979514">Free Full Text </a></span></li><li><a name=ref-195 class=n-a></a><span class=label>195. </span>&nbsp;<span class=citation><a name=d14871e7820 class=n-a></a>Meldolesi J: Extracellular vesicles, news about their role in immune cells: physiology, pathology and diseases. <i>Clin Exp Immunol.</i> 2019; <b>196</b>(3): 318327. <a target=xrefwindow id=d14871e7828 href="http://www.ncbi.nlm.nih.gov/pubmed/30756386">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7831 href="https://doi.org/10.1111/cei.13274">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7834 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6514371">Free Full Text </a></span></li><li><a name=ref-196 class=n-a></a><span class=label>196. </span>&nbsp;<span class=citation><a name=d14871e7843 class=n-a></a>Yatim N, Cullen S, Albert ML: Dying cells actively regulate adaptive immune responses. <i>Nat Rev Immunol.</i> 2017; <b>17</b>(4): 262275. <a target=xrefwindow id=d14871e7851 href="http://www.ncbi.nlm.nih.gov/pubmed/28287107">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7854 href="https://doi.org/10.1038/nri.2017.9">Publisher Full Text </a></span></li><li><a name=ref-197 class=n-a></a><span class=label>197. </span>&nbsp;<span class=citation><a name=d14871e7863 class=n-a></a>Kitai Y, Kawasaki T, Sueyoshi T, <i> et al.</i>: DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity. <i>J Immunol.</i> 2017; <b>198</b>(4): 16491659. <a target=xrefwindow id=d14871e7874 href="http://www.ncbi.nlm.nih.gov/pubmed/28069806">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7877 href="https://doi.org/10.4049/jimmunol.1601694">Publisher Full Text </a></span></li><li><a name=ref-198 class=n-a></a><span class=label>198. </span>&nbsp;<span class=citation><a name=d14871e7887 class=n-a></a>Iwai T, Sugimoto M, Wakita D, <i> et al.</i>: Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies. <i>Oncotarget.</i> 2018; <b>9</b>(59): 3141131421. <a target=xrefwindow id=d14871e7898 href="http://www.ncbi.nlm.nih.gov/pubmed/30140379">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7901 href="https://doi.org/10.18632/oncotarget.25830">Publisher Full Text </a> | <a target=xrefwindow id=d14871e7905 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6101148">Free Full Text </a></span></li><li><a name=ref-199 class=n-a></a><span class=label>199. </span>&nbsp;<span class=citation><a name=d14871e7914 class=n-a></a>Nitiss JL, Liu YX, Hsiung Y: A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. <i>Cancer Res.</i> 1993; <b>53</b>(1): 8993. <a target=xrefwindow id=d14871e7922 href="http://www.ncbi.nlm.nih.gov/pubmed/8380128">PubMed Abstract </a></span></li><li><a name=ref-200 class=n-a></a><span class=label>200. </span>&nbsp;<span class=citation><a name=d14871e7931 class=n-a></a>Nitiss JL, Rose A, Sykes KC, <i> et al.</i>: Using yeast to understand drugs that target topoisomerases. <i>Ann N Y Acad Sci.</i> 1996; <b>803</b>: 3243. <a target=xrefwindow id=d14871e7942 href="http://www.ncbi.nlm.nih.gov/pubmed/8993498">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7945 href="https://doi.org/10.1111/j.1749-6632.1996.tb26374.x">Publisher Full Text </a></span></li><li><a name=ref-201 class=n-a></a><span class=label>201. </span>&nbsp;<span class=citation><a name=d14871e7954 class=n-a></a>Bjornsti MA, Benedetti P, Viglianti GA, <i> et al.</i>: Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. <i>Cancer Res.</i> 1989; <b>49</b>(22): 631823. <a target=xrefwindow id=d14871e7965 href="http://www.ncbi.nlm.nih.gov/pubmed/2553253">PubMed Abstract </a></span></li><li><a name=ref-202 class=n-a></a><span class=label>202. </span>&nbsp;<span class=citation><a name=d14871e7974 class=n-a></a>Hann C, Evans DL, Fertala J, <i> et al.</i>: Increased camptothecin toxicity induced in mammalian cells expressing <i>Saccharomyces cerevisiae</i> DNA topoisomerase I. <i>J Biol Chem.</i> 1998; <b>273</b>(14): 842533. <a target=xrefwindow id=d14871e7988 href="http://www.ncbi.nlm.nih.gov/pubmed/9525954">PubMed Abstract </a> | <a target=xrefwindow id=d14871e7992 href="https://doi.org/10.1074/jbc.273.14.8425">Publisher Full Text </a></span></li><li><a name=ref-203 class=n-a></a><span class=label>203. </span>&nbsp;<span class=citation><a name=d14871e8001 class=n-a></a>Iqbal S, Lenz HJ: Determinants of prognosis and response to therapy in colorectal cancer. <i>Curr Oncol Rep.</i> 2001; <b>3</b>(2): 1028. <a target=xrefwindow id=d14871e8009 href="http://www.ncbi.nlm.nih.gov/pubmed/11177741">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8012 href="https://doi.org/10.1007/s11912-001-0008-5">Publisher Full Text </a></span></li><li><a name=ref-204 class=n-a></a><span class=label>204. </span>&nbsp;<span class=citation><a name=d14871e8022 class=n-a></a>Braun MS, Richman SD, Quirke P, <i> et al.</i>: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. <i>J Clin Oncol.</i> 2008; <b>26</b>(16): 26908. <a target=xrefwindow id=d14871e8033 href="http://www.ncbi.nlm.nih.gov/pubmed/18509181">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8036 href="https://doi.org/10.1200/JCO.2007.15.5580">Publisher Full Text </a></span></li><li><a name=ref-205 class=n-a></a><span class=label>205. </span>&nbsp;<span class=citation><a name=d14871e8045 class=n-a></a>Horisberger K, Erben P, Muessle B, <i> et al.</i>: Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. <i>Anticancer Drugs.</i> 2009; <b>20</b>(6): 51924. <a target=xrefwindow id=d14871e8056 href="http://www.ncbi.nlm.nih.gov/pubmed/19436196">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8059 href="https://doi.org/10.1097/CAD.0b013e32832b53ff">Publisher Full Text </a></span></li><li><a name=ref-206 class=n-a></a><span class=label>206. </span>&nbsp;<span class=citation><a name=d14871e8068 class=n-a></a>Nygrd SB, Vainer B, Nielsen SL, <i> et al.</i>: DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer. <i>Clin Cancer Res.</i> 2016; <b>22</b>(7): 163131. <a target=xrefwindow id=d14871e8079 href="http://www.ncbi.nlm.nih.gov/pubmed/26542057">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8082 href="https://doi.org/10.1158/1078-0432.CCR-15-0561">Publisher Full Text </a></span></li><li><a name=ref-207 class=n-a></a><span class=label>207. </span>&nbsp;<span class=citation><a name=d14871e8091 class=n-a></a>Di Leo A, Desmedt C, Bartlett JM, <i> et al.</i>: <i>HER2</i> and <i>TOP2A</i> as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. <i>Lancet Oncol.</i> 2011; <b>12</b>(12): 113442. <a target=xrefwindow id=d14871e8109 href="http://www.ncbi.nlm.nih.gov/pubmed/21917518">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8112 href="https://doi.org/10.1016/S1470-2045(11)70231-5">Publisher Full Text </a></span></li><li><a name=ref-208 class=n-a></a><span class=label>208. </span>&nbsp;<span class=citation><a name=d14871e8121 class=n-a></a>Du Y, Zhou Q, Yin W, <i> et al.</i>: The role of topoisomerase II in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures. <i>Breast Cancer Res Treat.</i> 2011; <b>129</b>(3): 83948. <a target=xrefwindow id=d14871e8132 href="http://www.ncbi.nlm.nih.gov/pubmed/21809115">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8135 href="https://doi.org/10.1007/s10549-011-1694-9">Publisher Full Text </a></span></li><li><a name=ref-209 class=n-a></a><span class=label>209. </span>&nbsp;<span class=citation><a name=d14871e8144 class=n-a></a>Patel AG, Flatten KS, Peterson KL, <i> et al.</i>: Immunodetection of human topoisomerase I-DNA covalent complexes. <i>Nucleic Acids Res.</i> 2016; <b>44</b>(6): 281626. <a target=xrefwindow id=d14871e8155 href="http://www.ncbi.nlm.nih.gov/pubmed/26917015">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8158 href="https://doi.org/10.1093/nar/gkw109">Publisher Full Text </a> | <a target=xrefwindow id=d14871e8162 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4824114">Free Full Text </a></span></li><li><a name=ref-210 class=n-a></a><span class=label>210. </span>&nbsp;<span class=citation><a name=d14871e8172 class=n-a></a>Nitiss J, Wang JC: DNA topoisomerase-targeting antitumor drugs can be studied in yeast. <i>Proc Natl Acad Sci U S A.</i> 1988; <b>85</b>(20): 75015. <a target=xrefwindow id=d14871e8180 href="http://www.ncbi.nlm.nih.gov/pubmed/2845409">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8183 href="https://doi.org/10.1073/pnas.85.20.7501">Publisher Full Text </a> | <a target=xrefwindow id=d14871e8186 href="http://www.ncbi.nlm.nih.gov/pmc/articles/282219">Free Full Text </a></span></li><li><a name=ref-211 class=n-a></a><span class=label>211. </span>&nbsp;<span class=citation><a name=d14871e8195 class=n-a></a>Samoulian V, Maugard CM, Jolicoeur M, <i> et al.</i>: Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in <i>BRCA2</i>, <i>TGFbeta-RII</i>, <i>KRAS2</i>, <i>TP53</i> and/or <i>CDNK2A</i>. <i>Cancer Chemother Pharmacol.</i> 2004; <b>54</b>(6): 497504. <a target=xrefwindow id=d14871e8222 href="http://www.ncbi.nlm.nih.gov/pubmed/15258697">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8225 href="https://doi.org/10.1007/s00280-004-0843-9">Publisher Full Text </a></span></li><li><a name=ref-212 class=n-a></a><span class=label>212. </span>&nbsp;<span class=citation><a name=d14871e8234 class=n-a></a>Fedier A, Steiner RA, Schwarz VA, <i> et al.</i>: The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. <i>Int J Oncol.</i> 2003; <b>22</b>(5): 116973. <a target=xrefwindow id=d14871e8245 href="http://www.ncbi.nlm.nih.gov/pubmed/12684687">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8248 href="https://doi.org/10.3892/ijo.22.5.1169">Publisher Full Text </a></span></li><li><a name=ref-213 class=n-a></a><span class=label>213. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/3171957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d14871e8257 class=n-a></a>Zander SA, Kersbergen A, van der Burg E, <i> et al.</i>: Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. <i>Cancer Res.</i> 2010; <b>70</b>(4): 170010. <a target=xrefwindow id=d14871e8268 href="http://www.ncbi.nlm.nih.gov/pubmed/20145144">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8271 href="https://doi.org/10.1158/0008-5472.CAN-09-3367">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/3171957">F1000 Recommendation</a></span></li><li><a name=ref-214 class=n-a></a><span class=label>214. </span>&nbsp;<span class=citation><a name=d14871e8285 class=n-a></a>Safra T, Rogowski O, Muggia FM: The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. <i>Int J Gynecol Cancer.</i> 2014; <b>24</b>(3): 48895. <a target=xrefwindow id=d14871e8293 href="http://www.ncbi.nlm.nih.gov/pubmed/24457564">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8296 href="https://doi.org/10.1097/IGC.0000000000000086">Publisher Full Text </a></span></li><li><a name=ref-215 class=n-a></a><span class=label>215. </span>&nbsp;<span class=citation><a name=d14871e8305 class=n-a></a>Tan DS, Kaye SB: Chemotherapy for Patients with <i>BRCA1</i> and <i>BRCA2</i>-Mutated Ovarian Cancer: Same or Different? <i>Am Soc Clin Oncol Educ Book.</i> 2015; 11421. <a target=xrefwindow id=d14871e8316 href="http://www.ncbi.nlm.nih.gov/pubmed/25993149">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8319 href="https://doi.org/10.14694/EdBook_AM.2015.35.114">Publisher Full Text </a></span></li><li><a name=ref-216 class=n-a></a><span class=label>216. </span>&nbsp;<span class=citation><a name=d14871e8329 class=n-a></a>Miyoshi Y, Kurosumi M, Kurebayashi J, <i> et al.</i>: Predictive factors for anthracycline-based chemotherapy for human breast cancer. <i>Breast Cancer.</i> 2010; <b>17</b>(2): 1039. <a target=xrefwindow id=d14871e8340 href="http://www.ncbi.nlm.nih.gov/pubmed/19657712">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8343 href="https://doi.org/10.1007/s12282-009-0152-6">Publisher Full Text </a></span></li><li><a name=ref-217 class=n-a></a><span class=label>217. </span>&nbsp;<span class=citation><a name=d14871e8352 class=n-a></a>Graeser M, McCarthy A, Lord CJ, <i> et al.</i>: A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. <i>Clin Cancer Res.</i> 2010; <b>16</b>(24): 615968. <a target=xrefwindow id=d14871e8363 href="http://www.ncbi.nlm.nih.gov/pubmed/20802015">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8366 href="https://doi.org/10.1158/1078-0432.CCR-10-1027">Publisher Full Text </a> | <a target=xrefwindow id=d14871e8370 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3432445">Free Full Text </a></span></li><li><a name=ref-218 class=n-a></a><span class=label>218. </span>&nbsp;<span class=citation><a name=d14871e8379 class=n-a></a>Zhang J, Zhou L, Zhao S, <i> et al.</i>: The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia. <i>Cell Cycle.</i> 2017; <b>16</b>(12): 11931200. <a target=xrefwindow id=d14871e8390 href="http://www.ncbi.nlm.nih.gov/pubmed/28486050">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8393 href="https://doi.org/10.1080/15384101.2017.1320005">Publisher Full Text </a> | <a target=xrefwindow id=d14871e8397 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5499912">Free Full Text </a></span></li><li><a name=ref-219 class=n-a></a><span class=label>219. </span>&nbsp;<span class=citation><a name=d14871e8406 class=n-a></a>Kummar S, Chen A, Ji J, <i> et al.</i>: Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. <i>Cancer Res.</i> 2011; <b>71</b>(17): 562634. <a target=xrefwindow id=d14871e8417 href="http://www.ncbi.nlm.nih.gov/pubmed/21795476">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8420 href="https://doi.org/10.1158/0008-5472.CAN-11-1227">Publisher Full Text </a> | <a target=xrefwindow id=d14871e8424 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3166628">Free Full Text </a></span></li><li><a name=ref-220 class=n-a></a><span class=label>220. </span>&nbsp;<span class=citation><a name=d14871e8433 class=n-a></a>Samol J, Ranson M, Scott E, <i> et al.</i>: Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. <i>Invest New Drugs.</i> 2012; <b>30</b>(4): 1493500. <a target=xrefwindow id=d14871e8444 href="http://www.ncbi.nlm.nih.gov/pubmed/21590367">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8447 href="https://doi.org/10.1007/s10637-011-9682-9">Publisher Full Text </a></span></li><li><a name=ref-221 class=n-a></a><span class=label>221. </span>&nbsp;<span class=citation><a name=d14871e8456 class=n-a></a>LoRusso PM, Li J, Burger A, <i> et al.</i>: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. <i>Clin Cancer Res.</i> 2016; <b>22</b>(13): 322737. <a target=xrefwindow id=d14871e8467 href="http://www.ncbi.nlm.nih.gov/pubmed/26842236">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8470 href="https://doi.org/10.1158/1078-0432.CCR-15-0652">Publisher Full Text </a> | <a target=xrefwindow id=d14871e8474 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4930710">Free Full Text </a></span></li><li><a name=ref-222 class=n-a></a><span class=label>222. </span>&nbsp;<span class=citation><a name=d14871e8484 class=n-a></a>Chen EX, Jonker DJ, Siu LL, <i> et al.</i>: A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. <i>Invest New Drugs.</i> 2016; <b>34</b>(4): 4507. <a target=xrefwindow id=d14871e8495 href="http://www.ncbi.nlm.nih.gov/pubmed/27075016">PubMed Abstract </a> | <a target=xrefwindow id=d14871e8498 href="https://doi.org/10.1007/s10637-016-0351-x">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Sep 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1704&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1704&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, 35294-0019, USA<br/> <sup>2</sup> Departments of Oncology and Molecular Pharmacolgy &amp; Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA<br/> <p> <div class=margin-bottom> Mary-Ann Bjornsti <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Validation, Writing  Review & Editing </div> <div class=margin-bottom> Scott H. Kaufmann <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Validation, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1704/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 30 Sep 2019, 8:1704 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.20201.1">https://doi.org/10.12688/f1000research.20201.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2019 Bjornsti MA and Kaufmann SH. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=22188 data-id=20201 data-downloads="" data-views="" data-scholar="10.12688/f1000research.20201.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1704/v1/pdf?article_uuid=46ee00b9-d4d9-47b2-9593-4f35a3e39253" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.20201.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Bjornsti MA and Kaufmann SH. Topoisomerases and cancer chemotherapy: recent advances and unanswered questions [version 1; peer review: 3 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1704 (<a href="https://doi.org/10.12688/f1000research.20201.1" target=_blank>https://doi.org/10.12688/f1000research.20201.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=20201 id=mobile-track-article-signin-20201 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/20201?target=/articles/8-1704"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=22188 /> <input name=articleId type=hidden value=20201 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Joseph Deweese</strong>, Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Lipscomb University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Yuk-Ching Tse-Dinh</strong>, Department of Chemistry and Biochemistry and Biomolecular Sciences, Florida International University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Anthony Maxwell</strong>, Department of Biological Chemistry, John Innes Centre, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Sep 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1704&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1704&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=57286-54096></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=57284-54094></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=57283-54093></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1704/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>30 Sep 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Joseph Deweese</strong>, Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Lipscomb University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Yuk-Ching Tse-Dinh</strong>, Department of Chemistry and Biochemistry and Biomolecular Sciences, Florida International University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Anthony Maxwell</strong>, Department of Biological Chemistry, John Innes Centre, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1704&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1704/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Topoisomerases and cancer chemotherapy: recent...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1704/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1704/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1704/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Bjornsti MA and Kaufmann SH');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1704/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1704",
            templates : {
                twitter : "Topoisomerases and cancer chemotherapy: recent advances and unanswered.... Bjornsti MA and Kaufmann SH, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1704/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Topoisomerases and cancer chemotherapy: recent advances and unanswered questions", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Topoisomerases and cancer chemotherapy: recent advances and unanswered questions", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/20201/22188")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "22188");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "54096": 2,
                           "54093": 0,
                           "54094": 3,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "19dbf59d-b7fb-4ca0-983c-9498e3ffb018";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1704.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1704.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1704.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1704.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1704.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>